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ABSTRACT OF THE DISSERTATION
Glucosensing, Hypoglycemia, and the Brain
By
Candace Michelle Reno
Doctor of Philosophy in Molecular Cell Biology
Washington University in St. Louis, 2013
Associate Professor Simon J. Fisher, Chairperson

Glucose homeostasis can be peripherally and centrally mediated. Within the periphery,
GLUT4 in muscle and adipose tissue is required for normal glucose homeostasis and
disruption of GLUT4 translocation in these tissues leads to glucose intolerance and
insulin resistance, hallmarks of Type 2 diabetes. Within the brain, specialized glucose
sensing neurons regulate whole body glucose homeostasis. Unlike GLUT4’s role in the
periphery, brain GLUT4 regulation of glucose tolerance is not well defined.
Understanding how brain glucose sensing, mediated by GLUT4, regulates glucose
tolerance and insulin sensitivity will aid in the development of treatment strategies to
protect against the pathogenesis of diabetes. In addition, the brain regulates
hypoglycemic counterregulation. Hypoglycemia is a major limitation to the treatment of
diabetes. Severe hypoglycemia can lead to brain damage, cognitive dysfunction, and
death. Understanding how to prevent the complications of severe hypoglycemia is
critical to helping patients that are at risk. This thesis investigated 1) the role of brain
GLUT4 in mediating peripheral insulin sensitivity, brain glucose sensing, and the
counterregulatory response to hypoglycemia, 2) the effect of chronic insulin therapy in
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protecting the diabetic brain against neuronal damage and cognitive dysfunction due to
severe hypoglycemia, and 3) the mechanisms by which severe hypoglycemia leads to
sudden death. Brain GLUT4 was shown to be critical for normal glucose homeostasis
and the counterregulatory response to hypoglycemia. This indicates that therapeutic
targeting strategies can aim to enhance brain GLUT4 function to improve glucose
homeostasis in the setting of diabetes. Chronic insulin therapy in diabetic rats
decreased the extent of brain damage due to severe hypoglycemia. This indicates that
insulin therapy in diabetes decreases susceptibility to severe hypoglycemia-induced
brain damage. The mechanisms of severe hypoglycemia induced sudden death are
shown for the first time to be regulated by sympathetic mediated fatal cardiac
arrhythmias. This thesis reveals the importance of the brain in the regulation of glucose
homeostasis and the counterregulatory response to hypoglycemia and reveals
paradoxical evidence that inhibition of the counterregulatory response acts to protect
against severe hypoglycemia-induced mortality.
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Chapter 1: Thesis Introduction

1

Diabetes
Diabetes is a growing epidemic with more than 25 million people in the US alone
diagnosed. Diabetes is defined by an elevated blood glucose resulting from
autoimmune destruction of pancreatic beta cells leading to insulin deficiency (Type 1
diabetes) or a combination of insulin resistance and beta cell failure (Type 2 diabetes).
Chronic hyperglycemia in diabetes can result in both macrovascular (heart disease,
stroke) and microvascular (neuropathy, nephropathy, retinopathy) complications. A
major contributor to glucose intolerance and insulin resistance in models of Type 2
diabetes is impaired glucose transporter 4 (GLUT4) expression and/or translocation to
the plasma membrane for insulin stimulated glucose uptake1,2. Insulin acts to lower
blood glucose levels by both suppressing endogenous glucose production as well as
increasing peripheral GLUT4-dependent glucose uptake. Impaired insulin action leads
to inefficient glucose uptake into muscle and adipose tissue as well as altered regulation
of hepatic glucose production resulting in hyperglycemia.
Because of its potent effects to lower blood glucose, insulin is used in the
treatment of diabetes to control blood glucose levels. However, insulin treatment leads
to increased risk of iatrogenic hypoglycemia. Hypoglycemia prevalence in insulin treated
diabetic patients is as high as 2.1 times per 24 hours3. To function properly, the brain is
constantly dependent on circulating glucose. Thus when severe, hypoglycemia can
result in seizures, brain damage4-6, cognitive decline4,7-9, coma, and even death10.
These are all major concerns for insulin treated diabetic patients and their families.
Determining the mechanisms of how hypoglycemia-induced brain damage, cognitive
decline, and sudden death are regulated is critically important in order to find treatments
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to protect patients who are at risk for hypoglycemia. This thesis will specifically address
1) the role of brain glucose transporter 4 in glucose homeostasis, 2) the role of
antecedent blood glucose control in reducing severe hypoglycemia induced brain
damage and cognitive dysfunction, and 3) the mechanisms by which severe
hypoglycemia can cause sudden death.

Glucose homeostasis
Regulation of glucose homeostasis is a tightly controlled process involving crosstalk between liver, skeletal muscle, adipose tissue, and the brain to maintain blood
glucose in a normal physiologic range. Insulin’s actions in the periphery to lower blood
glucose levels have been studied extensively but its central actions have just begun to
be elucidated. The brain has an important role in energy homeostasis due to its
requirements for a constant glucose supply. Thus, studying the brain’s role in sensing
and responding to changes in glucose will aid in development of better strategies to
treat or prevent diabetes.

Anatomy of brain glucose sensing
Although all brain cells utilize glucose, only a few specialized neurons in the brain
truly sense and respond to a reduced glucose supply. Rodent studies indicate that
glucose is sensed in brain regions known to be important in metabolism and energy
homeostasis, particularly in the hypothalamus, where glucose sensing neurons are
located11. Most studies to date indicate that it is the hypothalamus that principally
initiates (or at least coordinates) the counterregulatory response (CRR) to hypoglycemia
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by stimulating hormone secretion in the pituitary gland, pancreas, and adrenal glands
resulting in a coordinated response (Figure 1). Clinical studies confirm the importance of
the hypothalamus as a critical glucose sensing area because blood flow to the
hypothalamus

increases

significantly

during

hypoglycemia,

even

before

counterregulatory hormones rise12. Within the hypothalamus, key regions that respond
to changes in circulating glucose levels are the ventromedial hypothalamus (VMH)
which contains the ventromedial nucleus (VMN) and the arcuate nucleus (ARC)13.
Studies show that glucose infusion into the VMH in the setting of peripheral
hypoglycemia blunts the epinephrine counterregulatory response to hypoglycemia14,15.
These studies indicate that decreases in glucose are detected by the VMH and are
required to fully activate the sympathoadrenal response to hypoglycemia.
The VMH contains glucose excitatory (GE, increases in glucose increase
neuronal activity) and glucose inhibited (GI, increases in glucose decrease neuronal
activity) neurons16. Together, the actions of these neurons results in a coordinated
process of trying to maintain plasma glucose levels within a normal physiological range.
It is thought that in response to hypoglycemia, concerted activation of GI neurons and
suppression of GE neurons, as an initiating part of a neural network, result in a
coordinated efferent process that activates the sympathoadrenal response. This
balance is disrupted in conditions such as diabetes17.

Brain glucose uptake
The brain contains different isoforms of glucose transporters (GLUT) responsible
for neuronal and astrocyte glucose uptake. The ubiquitous GLUT1 and the neural
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specific GLUT3 are the primary isoforms present in the brain that are responsible for
glucose transport across the blood brain barrier and into the brain. Based on discrete
regional expression, the potential contribution of other glucose transporters has been
investigated. A role for GLUT2 in mediating CNS glucose sensing has been proposed 18.
In addition, because of its important role in peripheral glucose tolerance, the insulinsensitive brain GLUT4 has been hypothesized to play a role in glucose and energy
homeostasis.

Glucose transporter 4
GLUT4 is an insulin sensitive facilitative glucose transporter primarily expressed
in adipose tissue, skeletal muscle, and heart19 with a lower expression in the brain20.
GLUT4 is expressed in various regions of the brain, including the hypothalamus (VMH,
PVN, ARC), cerebellum, hippocampus, and cortex21, regions important in metabolism,
learning, and memory. Translocation of intracellular GLUT4 to the plasma membrane in
adipose tissue and skeletal muscle is important in maintaining glucose homeostasis.
Altered GLUT4 translocation in adipose tissue and muscle leads to glucose intolerance
and insulin resistance, both characteristics of Type 2 diabetes1,2. It has been
hypothesized that brain GLUT4 works in a parallel insulin-dependent manner to that in
the periphery. Similar to its known actions in peripheral tissues, GLUT4 translocation
occurs in neuronal cell lines, hippocampus, and hypothalamus in response to insulin 2224

. In addition, studies have shown that GLUT4 expression in the brain is altered in

response to insulin levels. Diabetic mice (db/db, hyperinsulinemia) have increased
GLUT4 protein expression while streptozotocin induced diabetic rats (hypoinsulinemia)
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have decreased GLUT4 protein expression in the cerebellum25. In addition, ob/ob mice
(insulin resistant) have increased GLUT4 expression in the hypothalamus 25. Therefore,
regulation of GLUT4 protein expression in different regions of the brain may be
dependent on plasma insulin levels or insulin sensitivity, indicating a potential
pathogenic role for brain GLUT4 in the development of diabetes.
In addition to insulin regulation of brain GLUT4 protein expression and
translocation, co-localization of GLUT4 and insulin receptor (IR) within the brain
indicates an important relationship in the regulation of metabolism. Within the VMH, up
to 75% of the glucose sensing neurons co-express GLUT4 and IR16. Insulin receptors
are also highly expressed in the paraventricular nucleus (PVN) and arcuate nucleus
(ARC) of the hypothalamus26 suggesting an important role for brain insulin action in
metabolism. A recent report from our laboratory has shown the importance of insulin
action in the brain in mediating both glucose sensing and the counterregulatory
response to hypoglycemia. Neuronal insulin receptor knockout (NIRKO) mice have
impaired hypoglycemic counterregulation, characterized by a blunted epinephrine and
norepinephrine response27. Consistent with insulin exerting its effect primarily in the
hypothalamus, NIRKO mice have impaired glucose sensing in VMH GI neurons and
impaired activation of PVN neurons in response to hypoglycemia 27. In addition, insulin
induced suppression of hepatic glucose production is impaired in NIRKO mice,
confirming earlier reports of central insulin regulation of hepatic glucose production 28.
Together, these studies implicate hypothalamic insulin signaling as an important
regulator of glucose sensing to control hepatic glucose production and the normal
counterregulatory response to hypoglycemia. Interestingly, NIRKO mice have a 68%
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reduction in hypothalamic GLUT4 protein expression indicating that insulin’s actions in
metabolic homeostasis may be mediated in part by brain GLUT4.
Because peripheral GLUT4 is important in the etiology of type 2 diabetes and
brain GLUT4 is co-localized with the insulin receptor and its protein expression may be
controlled by insulin, a brain GLUT4 KO (BG4KO) mouse was generated to study the
importance

of

brain

GLUT4

in

glucose

homeostasis

and

hypoglycemic

counterregulation and is the focus of chapter 2.

Hypoglycemia
The treatment of diabetes remains suboptimal due to the barrier of iatrogenic
hypoglycemia. Insulin treated diabetic patients experience an average of two
symptomatic hypoglycemic episodes per week while severe hypoglycemia requiring
assistance is experienced approximately once per year29. Since the brain is
continuously dependent

on

glucose

for metabolism,

robust

counterregulatory

mechanisms exist to rapidly increase blood glucose levels in order to protect the brain
from hypoglycemia induced neuronal dysfunction and injury. Both severe and even
more moderate episodes of hypoglycemia can be harmful. Recurrent episodes of
moderate hypoglycemia can lead to a decreased awareness of hypoglycemia and
decreased counterregulation, a phenomenon known as hypoglycemia associated
autonomic failure (HAAF)30. HAAF can lead to an increased risk of more severe
episodes of hypoglycemia31. Severe hypoglycemia can alter brain structure4-6, cause
brain damage4-6, cognitive dysfunction4,7-9 and sudden death10. The counterregulatory
response (CRR) to hypoglycemia has an important role in preventing the fall in glucose
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to reduce the risk of the damaging effects of severe hypoglycemia, but, paradoxically,
this same response can be harmful, leading to increased susceptibility to the damaging
effects of severe hypoglycemia.

The counterregulatory response to hypoglycemia
In the setting of absolute or relative hyperinsulinemia, the CRR is normally
initiated when glucose levels fall below 80 mg/dl. The CRR to hypoglycemia normally
includes suppression of endogenous insulin secretion and increased secretion of
catecholamines (epinephrine, norepinephrine), glucagon, cortisol, and growth hormone,
which together act to increase plasma glucose levels by stimulating hepatic glucose
production and limiting glucose utilization in peripheral tissues (Figure 1).

Sympathetic activation
In response to hypoglycemia, patients with Type 1 diabetes and advanced Type
2 diabetes are not able to suppress circulating (exogenous) insulin levels nor increase
glucagon secretion32. Thus, in the absence of appropriate insulin and glucagon
responses, patients with diabetes rely extensively on the sympathoadrenal system as
their primary counterregulatory defense against hypoglycemia 33. Adrenergic activation
leads to the release of norepinephrine at nerve terminals located throughout the
periphery. Within the adrenal gland, adrenergic stimulation leads to epinephrine
secretion. Activation of the adrenergic system reverses falling glucose levels by
increasing glucose production, reducing peripheral glucose utilization, and eliciting
symptoms of hypoglycemia.
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Catecholamines
As systemic blood glucose levels fall, glucose levels within the brain also
decrease. A fall in glucose levels within the VMH is associated with increased
norepinephrine release in the VMH and the initiation of the counterregulatory response
to hypoglycemia34,35. Adrenergic receptors within the brain, particularly the VMH, are
important mediators that trigger the sympathoadrenal response to hypoglycemia 36.
However, recurrent episodes of hypoglycemia can lead to a blunted counterregulatory
response to subsequent hypoglycemia as well as hypoglycemia unawareness,
characteristics of HAAF. A recent study by Ramanathan et al.37 showed that
intravenous infusion of adrenergic blockers (phentolamine and propranolol) on day 1 of
hypoglycemia prevented the induction of counterregulatory failure in the subsequent
response on day 2 of hypoglycemia. This study implicates that HAAF is induced by
antecedent sympathoadrenal responses to hypoglycemia. Taken together, extending
these findings to their potential pharmacologic and therapeutic implications indicates
that paradoxically blocking the action of catecholamines within the CNS may protect
against subsequent hypoglycemic bouts by limiting the development of HAAF, but
unfortunately, blocking the action of catecholamines in the periphery would tend to
increase the severity of acute hypoglycemia. Future research is needed to develop CNS
specific adrenergic blockers that alter brain mediated counterregulatory responses
without disrupting the peripheral sympathoadrenal response.
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Glucagon
In addition to an impaired sympathoadrenal response to hypoglycemia, insulin
deficient diabetes also results in loss of the glucagon counterregulatory response to
hypoglycemia38. The mechanisms that regulate glucagon secretion during hypoglycemia
are unclear32. Recent work suggests multiple mechanisms of regulation of glucagon
secretion including fall in glucose levels, intra-islet crosstalk39, and autonomic
stimulation40.
In response to hypoglycemia the counterregulatory glucagon response may be
mediated, as least in part, via direct action on pancreatic cells41,42. In addition, other
mechanisms of intra-islet control of glucagon secretion during hypoglycemia exist
including  cell signaling41, indirect  cell to  cell signaling43,44, and cell secretory
products45. In particular,  cell somatostatin secretion can stimulate glucagon secretion
during hypoglycemia45. Somatostatin within the pancreas and in circulation is elevated
in diabetes46 and may contribute to the defective glucagon response during
hypoglycemia. A recent study showed that the glucagon response to hypoglycemia in
diabetic rats can be restored by somatostatin receptor type 2 antagonism accomplished
by infusion of a selective somatostatin receptor type 2 antagonist during hypoglycemia
in streptozotocin-induced diabetic rats47. Pancreatic glucagon was elevated in diabetic
rats suggesting that there is a glucagon secretory defect in diabetic rats during severe
hypoglycemia rather than a glucagon synthesis defect. These studies suggest that
elevated somatostatin in diabetes is one mechanism in which the glucagon response is
lost during hypoglycemia.
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Autonomic inputs of the pancreas include actions from both the parasympathetic
and sympathetic nervous systems. Parasympathetic activation includes secretion of
acetylcholine (AcH), which bind to receptors directly on the  and cells48. The
sympathetic nervous system releases norepinephrine48. Norepinephrine acts on 2
adrenergic receptors present on pancreatic  cells to stimulate glucagon secretion49. In
addition, the sympathoadrenal system results in release of AcH in adrenal medulla cells
to release epinephrine which acts on the pancreas to stimulate glucagon secretion50.
The redundant mechanisms involved in the regulation of glucagon secretion makes the
defects in diabetes more interesting in that many mechanisms have to fail in order get
impaired glucagon secretion. Determining which factors are necessary and sufficient for
glucagon secretion can potentially help patients at risk for recurrent hypoglycemia
(impaired epinephrine responses) better combat hypoglycemic bouts in order to prevent
severe hypoglycemia.

Severe hypoglycemia
Defects in the brain’s ability to sense changes in glucose levels can lead to
impairments in the hypoglycemia induced counterregulatory response, which in a
viscous cycle can lead to more severe episodes of hypoglycemia characterized by brain
damage, cognitive impairment, and even death. Understanding the mechanisms that
lead to severe hypoglycemia-induced brain damage and sudden death is important to
help patients who are at risk for hypoglycemia.
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Hypoglycemia and brain damage
Acute severe hypoglycemia induces neuronal damage in the cortex and
hippocampus51-53. Deficits in learning and memory have been shown to be a direct
consequence of severe hypoglycemia-induced hippocampal neuronal damage51,53,54.
However, clinical studies investigating severe hypoglycemia effects on cognition have
been variable, with some demonstrating7,55,56 and others not demonstrating57-59
cognitive problems. In our laboratory, a rat model of recurrent hypoglycemia revealed
that brain damage and cognitive defects induced by severe hypoglycemia could be
protected by exposure to recurrent moderate hypoglycemia 60 demonstrating a functional
relationship between brain damage and long-term cognitive function. In addition, it has
been reported in our lab that diabetes per se increases the extent of severe
hypoglycemia induced neuronal damage61, but neither the effects on long term cognitive
function nor the effects of insulin treatment were studied. Consistent with the notion that
insulin deficiency worsens outcomes following brain insults, insulin has been shown to
protect cells from death in both in vitro62-66 and in vivo67,68 studies. It was hypothesized
that restoration of near normal glucose levels with chronic insulin therapy in diabetic rats
protects against severe hypoglycemia-induced brain damage and cognitive dysfunction
and is the focus of chapter 3.

Hypoglycemia and Mortality
Although fortunately rare, severe hypoglycemia can be lethal. The sudden
unexplained death of patients with Type 1 diabetes has been noted by Tattersall and
Gill69 and others70-78 with death 10-fold higher in young people with Type 1 diabetes 78.
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The “dead in bed syndrome” identifies otherwise healthy young individuals with Type 1
diabetes that were found dead in bed with no clear cause of death75,77,79. Recent case
reports consistently suggest that severe hypoglycemia due to excess insulin
administration contributed to their death70-74,76,77,80. Given the rise of the number of
cases of the dead in bed syndrome, research is needed in order to understand the
mechanisms by which severe hypoglycemia can be lethal.
Central nervous system glucopenia is thought to be the major contributor to
severe hypoglycemia-induced mortality. The brain cannot function properly without a
continuous supply of glucose from the blood. During hypoglycemia, lack of brain
glucose can lead to neuronal damage81 and seizures82,83 both of which may increase
susceptibility to mortality. For instance, studies of sudden death in epileptic patients
showed that seizures triggered an autonomic response leading to fatal cardiac
arrhythmias84. In our model of insulin induced severe hypoglycemia, lack of brain
glucose leads to seizures60,61; however, whether or not seizures correlate with
increased risk of fatal cardiac arrhythmias in the setting of severe hypoglycemia is
unknown.
Acute onset cardiac arrhythmias are speculated to be the primary cause of
severe hypoglycemia-induced sudden death. Clinical studies using electrocardiograms
(ECG) have found that cardiac arrhythmias associated with QTc prolongation occur
during moderate hypoglycemia in both healthy and diabetic patients85-90. QTc
prolongation represents dispersion of ventricle depolarization and repolarization and
can lead to increased risk of fatal cardiac arrhythmias 91-94. However, due to the difficulty
of studying the complications of severe hypoglycemia in a clinical setting, studies are
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unable to confirm that fatal cardiac arrhythmias result from severe hypoglycemia in the
human population.
In addition to central nervous system counterregulation to hypoglycemia,
systemic regulation of hypoglycemia can lead to cardiac arrhythmias 74,85-87. It is well
established that enhanced catecholamine levels can cause ventricular arrhythmias95,96.
In addition, patients exposed to moderate levels of hypoglycemia (~45 mg/dl)
experienced cardiac arrhythmias associated with QTc prolongation that could be
rescued with potassium or beta blocker infusion88. In the setting of insulin-induced
hypoglycemia, both the insulin induced decrease in potassium levels and the
counterregulatory induced increase in catecholamine levels have been speculated to
contribute to fatal cardiac arrhythmias88,97-99. This thesis tests the hypothesis that the
prevention of hypokalemia and/or adrenergic receptor blockade protects against
arrhythmias and cardiorespiratory arrest during severe hypoglycemia. It also examines
the extent to which cardiac arrhythmias are centrally mediated. Whether central or
systemic, possible mechanisms by which fatal cardiac arrhythmias occur during severe
hypoglycemia are increased catecholamine surge88,97, hypokalemia88,97,

seizures81,

and/or hypoxemia that occurs with apneic episodes100. Exploration of these potential
mediators of sudden death due to severe hypoglycemia is the focus of chapter 4.

Summary
The brain has recently been shown to be an important regulator of whole body
glucose homeostasis, but how the brain plays a role in the pathogenesis of diabetes is
not well defined. Brain-mediated metabolic regulation has implications for the
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development of drug targeting strategies that can target the brain without adverse
effects on peripheral metabolism. In addition, diabetes treatment strategies are currently
limited due to the concern of iatrogenic hypoglycemia. Therefore, this thesis aims to
address how brain glucose sensing controls peripheral metabolism and how the
complications of severe hypoglycemia induced brain damage and mortality can be
prevented.
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Figure 1. The counterregulatory response to hypoglycemia. Hypoglycemia is first
sensed in various brain regions including the hypothalamus (HYP) and brain stem. Low
glucose in these brain regions stimulates the autonomic nervous system to release
norepinephrine and acetylcholine at postganglionic nerve terminals. A principal
counterregulatory response is the secretion of glucagon which may be stimulated by
various mechanisms including independent α-cell glucose sensing, autonomic
innervation, epinephrine stimulation, and a decrement of intra-islet insulin secretion. Via
autonomic stimulation, epinephrine is released from the adrenal medulla. Not shown is
the hypothalamic-pituitary-adrenal axis by which the release of adrenocorticotropic
hormone (ACTH) from the pituitary stimulates cortisol release from the adrenal cortex.
The net effect of the autonomic nervous system and counterregulatory hormones is to
act at the level of the liver to increase hepatic gluconeogenesis and glycogenolysis
while action at muscle and adipose tissue (fat) decrease peripheral glucose utilization.
16

Chapter 2. Glucose Intolerance, Insulin Resistance, and Impaired Hypoglycemic
Counterregulation in Brain GLUT4 Knockout Mice

17

Abstract
The role of insulin-responsive glucose transporter 4 (GLUT4) in the central nervous
system has not been well characterized. To assess its importance, a selective knockout of brain GLUT4 (BG4KO) was generated by crossing Nestin-Cre mice with GLUT4floxed mice. BG4KO mice had a 99% reduction in brain GLUT4. Despite normal fed and
fasting glycemia, BG4KO mice were glucose intolerant, demonstrated hepatic insulin
resistance, and had reduced brain glucose uptake during a hyperinsulinemic clamp. In
response to hypoglycemia, BG4KO mice had impaired glucose sensing noted by
impaired epinephrine and glucagon responses and impaired c-fos activation in the
hypothalamic paraventricular nucleus. Moreover, in-vitro glucose sensing of glucose
inhibitory neurons from the ventromedial hypothalamus was impaired in BG4KO mice.
In summary, glucose intolerance, insulin resistance, and impaired glucose sensing in
BG4KO mice indicate a critical role for brain GLUT4 in sensing and responding to
changes in blood glucose.
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Introduction
The facilitative glucose transporter 4 (GLUT4) is the major glucose transporter in
skeletal muscle, heart, and adipose tissue. In response to insulin stimulation, GLUT4 is
translocated to the plasma membrane to facilitate glucose entry into the cell101,102.
Disruption of GLUT4 in either skeletal muscle or adipose tissue leads to impaired
glucose tolerance and insulin resistance, two prominent features associated with the
pathogenesis of diabetes1,2. GLUT4 is also expressed in the brain21, although the
physiological role of GLUT4 in the brain has yet to be elucidated. The level of brain
GLUT4 protein expression appears to be dependent on insulin levels, as the diabetic
hyperinsulinemic db/db mouse has increased GLUT4 expression while the insulin
deficient

streptozotocin

diabetic

rodent

has

reduced

brain

GLUT4

levels103.

Interestingly, neuronal insulin receptor knockout (NIRKO) mice have a 68% reduction in
hypothalamic GLUT4 protein27. Together, this suggests a potential important role of
insulin responsive GLUT4 in the brain.
GLUT4 is expressed predominantly in neuronal cells in discrete regions of the
brain, including the hippocampus, cortex, and cerebellum. Of particular interest is that
GLUT4 is also expressed in the hypothalamus, an area important in the regulation of
whole body glucose and energy homeostasis21. Interestingly, GLUT4 is co-expressed
with the insulin receptor in glucose sensing neurons16. Whether dependent or
independent of brain insulin action, GLUT4 is strategically located to play an important
role in the neuronal glucose sensing and modulating whole body glucose homeostasis.
To determine the physiological role of GLUT4 in the brain, GLUT4 was
selectively knocked-out in the brain using a Cre-Lox approach and the effects on whole
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body glucose homeostasis were examined. Mice with brain specific GLUT4 knock-out
(BG4KO) were found to be glucose intolerant, have reduced insulin sensitivity, impaired
counterregulatory responses to hypoglycemia and impaired hypothalamic glucose
sensing in glucose inhibited (GI) neurons. Thus, these studies identify a novel role for
brain GLUT4 in regulating whole body energy homeostasis.
These studies are part of co-authored work with a previous graduate student,
Erwin Puente. There was equal contribution to the writing and execution of the
experiments. I helped write and fully revise the text for this section. I maintained the
mouse colony. The experiments which I conducted were the hyperinsulinemic,
euglycemic clamps and all assays associated with them including glucose turnover and
glucose uptake in brain, adipose, and skeletal muscle. I performed all experiments for
western blots of hypothalamic and liver pAkt and Insulin receptor. I performed the
hyperinsulinemic, hypoglycemic clamps for the whole body GLUT4 knockout mice and
also did the c-fos assays for that experiment. I also set up the collaboration with V
Routh for the electrophysiology studies conducted in her lab. I helped with many of the
other experiments described in this chapter.

Methods
Animals. To create brain specific GLUT4 KO mice, GLUT4 floxed mice 1,2,104
were crossed with transgenic mice that expressed Cre recombinase under the neuron
specific promoter nestin105-107. Male mice of the C57Bl6 background were used at 2-4
month of age in all studies unless otherwise specified. The 4 experimental groups
were: wild-type mice (GLUT4(+/+);nestin-Cre(-/-)); mice that have both GLUT4 alleles

20

floxed (GLUT4(lox-lox);nestin-Cre(-/-)); mice expressing Cre under the nestin promoter
(GLUT4(+/+);nestin-Cre(+/-)); and brain specific GLUT4 knockout mice (GLUT4 (loxlox)

;nestin-Cre(+/-)). For whole body GLUT4 knockout studies, Zona pellucida Cre mice

were crossed with GLUT4 lox mice and generously provided by B. Kahn. Mice were
genotyped by PCR analysis of DNA extracted from tail tissue using previously
established primers and PCR conditions1,2,105,106.
Mice and male Sprague-Dawley rats were housed in a temperature and light
controlled environment maintaining the animal’s diurnal cycle (12hrs light, 12hrs dark)
and fed a standard rodent chow ad libitum. All procedures were in accordance with the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health
and were approved by the Animal Studies Committee of Washington University.

Western blot analysis. Brain, skeletal muscle, heart, and white adipose tissue were
homogenized, centrifuged, and transferred to nitrocellulose membrane (Bio-Rad,
Hercules, CA), and were immunoblotted with antibodies against GLUT1 (1:1000,
Chemicon, Temecula, CA), GLUT3 (1:2000, Chemicon, Temecula, CA), GLUT4
(1:1000, Chemicon, Temecula, CA), or against the loading control β-actin (1:6000;
Sigma, St. Louis, MO)27. Hypothalamus and liver were immunoblotted with antibodies
against pAKT (1:500, Cell Signaling, Danvers, MA), tAKT (1:500, Cell Signaling,
Danvers, MA) Insulin Receptor anti-CD220, 1:500 BD Biosciences, San Jose, CA
and β-actin from 5 hour fasted mice 30 minutes (hypothalamus) or 15 minutes (liver)
after intraperitoneal injection of human regular insulin (3U/kg body weight) or saline
injection. Horseradish peroxidase-conjugated secondary antibody (1:8000, Cell
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Signaling, Boston, MA) was used and antibody binding was detected by enhanced
chemiluminescence ECL reagents (Perkin Elmer, Waltham, MA) on ISO-MAX films and
quantified by ImageJ software analysis.

Glucose and insulin tolerance tests. Glucose tolerance tests (GTT) were
accomplished by intraperitoneal injection of glucose (2 g glucose/kg body weight) after
an overnight fast (15-17 hr). Tail vein blood samples (20 μl) were taken before injection
and at 15 minute intervals during the GTT to measure plasma insulin levels. Insulin
tolerance tests (ITT) were performed in 5 hour fasted mice by intraperitoneal injection of
human regular insulin (1 U insulin/kg body weight; Lilly, Indianapolis, Indiana). Tail vein
blood glucose was measured using Ascensia Contour (Bayer HealthCare, LLC,
Mishawaka, IN) blood glucose monitors.

Glucose stimulated insulin secretion. First phase glucose stimulated insulin secretion
in overnight (15-17 hr) fasted mice was assessed following an intraperitoneal injection
of glucose (3 g glucose/kg body weight). Tail vein blood samples (20 μl) were taken for
glucose and insulin determinations immediately before injection and at 2, 5, 15, and 30
minutes after injection.

Hyperinsulinemic-euglycemic clamp, glucose kinetics analysis, and brain glucose
uptake. Hyperinsulinemic (4 mU.kg-1.min-1)-euglycemic (~110 mg/dl) clamp studies
were performed as previously described108. Micro-renathane catheters (Braintree
Scientific Inc., Braintree, Massachusetts, USA) were implanted in the jugular vein and
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femoral artery of anesthetized mice (Ketamine 87 mg/kg and Xylazine 2.6 mg/kg).
Hyperinsulinemic-euglycemic clamp studies were conducted 5–8 days after surgery in
awake, freely mobile mice after a 5-hour fast. Whole-body glucose flux was determined
using a continuous infusion of [3-3H] glucose (PerkinElmer, Boston, Massachusetts,
USA) at 0.05 μCi/min after an initial 5-μCi bolus. After a 90 minute basal period,
samples were taken for basal plasma insulin levels and plasma [ 3H]-glucose
measurements. A primed (40 mU/kg) continuous infusion (4 mU.kg-1.min-1) of human
regular insulin (Humulin; Eli Lilly and Co.) in 0.1% BSA was co-administered with 50%
glucose at variable rates to maintain blood glucose at approximately 110 mg/dl.
Tissue-specific insulin-stimulated glucose uptake was measured with a bolus (5
μCi) of 2-deoxy-D-[1-14C] glucose (2-[14C]DG; Amersham) administered 45 minutes
before the end of the clamp. For plasma 2-[14C]DG measurements, blood samples were
taken immediately before 2-[14C]DG administration and at 0.5, 2, 3, 5, 10, 15, 20, 30,
and 45 min following administration. Blood samples were taken at the end of the clamp
for plasma [3H]glucose and plasma insulin measurements. Immediately following the
clamp, mice were euthanized and skeletal muscle and adipose tissue were rapidly
dissected and frozen in liquid nitrogen. Brains were harvested and quickly frozen in a
dry ice and 2-methylbutane (Fisher, Saint Louis, MO) bath (-20o C). Plasma [3-3H]
glucose and 2-[14C]DG concentrations were determined by a dual-channel scintillation
counter (Tri-Carb 2800TR, PerkinElmer, Waltham, MA) after deproteinization and
drying. Tissue 2-[14C]DG and 2-[14C]DG-6-phosphate (2-[14C]DG-6P) were separated by
ion-exchange chromatography.
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Whole-body glucose turnover was determined at steady state from the ratio of
the [3H] glucose infusion rate to the measured specific activity of plasma glucose 108.
Hepatic glucose production (HGP) was determined by subtraction of the glucose
infusion rate from the whole-body glucose turnover108. Skeletal muscle and adipose
tissue glucose uptake was calculated from tissue 2-[14C]DG-6P content normalized
against the area under the plasma 2-[14C]DG decay curve109.
For brain glucose uptake calculations, isotope concentrations in regions of
interest were measured from 20μm thick coronal serial sections after exposure to
autoradiograph film via optical densitometry. Precise identification of the areas of
interest (paraventricular nucleus of the hypothalamus (PVN), arcuate nucleus (ARC),
ventromedial hypothalamus (VMH), hippocampus, cerebellum, and cortex) were
accomplished by Nissl staining the desired areas (figure 4). Mean local rates of glucose
utilization were calculated according to Sokoloff’s equation with rat rate constants, as
mice rate constants have not been calculated110,111.

Hyperinsulinemic-hypoglycemic

mice

clamps

and

c-fos

immunostaining.

Hyperinsulinemic (20 mU.kg-1.min-1) hypoglycemic (~30 mg/dl) clamps were performed
as previously described27. Four month old mice underwent 2 hour hyperinsulinemic (20
mU.kg-1.min-1) hypoglycemic (30 mg/dl) clamps as previously described27. A variable
12.5% glucose infusion was used to carefully match blood glucose levels to 30 mg/dl.
Blood samples were taken in the basal period and at the end of the clamp for hormone
assays.
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At the end of the 2 hr hypoglycemic clamp, mice were anesthetized with
isofluorane and intracardially perfused with 0.01 M PBS (Sigma, Saint Louis, MO)
followed by 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA). The
brains were immersed in 4% paraformaldehyde overnight and then cryoprotected in
30% sucrose. Brain sections were then processed for c-fos immunostaining27. Four
anatomically matched sections per animal were used to quantify c-fos immunostaining
in the paraventricular nucleus of the hypothalamus (PVN).
To test brain glucose sensing in a different model of GLUT4 knockout mice,
hyperinsulinemic (120mU.kg-1.min-1) hypoglycemic (~35 mg/dl) clamps were performed
in 5 week old whole body GLUT4 knockout mice created by crossing floxed GLUT4
mice wth zona pellucida Cre expressing mice. The resultant KO mice lacked GLUT4 in
all tissues, including the brain. During the hypoglycemic clamp, variable 50% glucose
was infused to match blood glucose levels, as described above.

Heat Stress. Awake BG4KO and littermate control mice were exposed to an ambient
temperature of 42°C for 60 minutes to induce heat stress. Arterial blood samples were
taken from an indwelling cannula before and at the end of the heat stress period to
measure epinephrine levels.

Analytical measurments. Blood glucose was measured by Ascensia Contour blood
glucose monitors (Bayer) and plasma glucose was assayed by the glucose oxidase
method and a spectrophotometer (BioTek Instruments, Inc., Winooski, VT).

Insulin

levels were measured by enzyme-linked immunosorbent assay (ELISA) (Crystal Chem,
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Chicago, Illinois). Catecholamine analysis was performed by a single isotope-derived
(radioenzymatic) method112. Radioimmunoassays were performed for glucagon (Linco
Research, St. Charles, MO) and corticosterone (MP Biomedicals, Orangeburg, NY)
measurements.

Pharmacological inhibition of brain GLUT4 by indinavir (IDV). Following recovery
from intracerebroventricular cannula (Plastics One Inc, Roanoke, VA) and vascular
implantation surgery, nine week-old male Sprague Dawley rats were subjected to a
hyperinsulinemic (20 mU.kg-1min-1) hypoglycemic clamp (~45 mg/dl) as previously
described113. Three hours prior to the start of, and for the duration of the clamp,
indinavir (10μg/min; Merck, White-house City, NJ) or vehicle (artificial cerebrospinal
fluid, aCSF) was infused into the third ventricle. Indinavir is a pharmacologic agent that
has been shown to inhibit GLUT4 activity and transport in cell culture and hippocampal
brain slices114-116. Arterial blood samples were taken in the basal period and at 45, 60,
and 90 min into the hyperinsulinemic clamp.

Electrophysiological studies. BG4KO and nestin-Cre positive littermate control mice
(28-42 day old) were anesthetized and brains sectioned as previously described 27. VMH
GI neurons from both control and BG4KO mice were identified as reversibly depolarized
and increased their action potential frequency and input resistance in response to a
glucose decrease from 2.5 to 0.1mM. Input resistance was calculated by dividing the
membrane voltage change (mV) by the current (pA). The effects of glucose and insulin
(5nM) on action potential frequency, membrane potential and input resistance were
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evaluated in current-clamp recordings (standard whole-cell recording configuration)
from neurons in the VMH as previously described27,117,118. Current-voltage relationships
were determined in the voltage-clamp recording mode using 10mV voltage steps from 50 to -150mV from a holding potential of -60mV.

Statistical analyses. All data are presented as the mean  standard error of the mean
(SEM). Statistical significance was set at p<0.05 and was determined by either
Student’s t test or analysis of variance (ANOVA), as indicated.

RESULTS
Verification of brain-specific GLUT4 deletion
Using the Cre-Lox system, brain specific GLUT4KO mice were created by
crossing mice that express Cre driven by the nestin promoter with mice that have exon
10 of GLUT4 flanked by loxP1,2,104. Four experimental groups were chosen for
phenotypic analysis: wild-type mice (WT); mice that have both GLUT4 alleles floxed
(Lox); mice expressing Cre under the nestin promoter (Cre); and brain specific GLUT4
knockout mice (BG4KO) that are homozygous GLUT 4 floxed and express Nestin Cre.
To verify tissue specific deletion of GLUT4, GLUT4 protein concentration was measured
by Western Blot analysis in the brain as well as the muscle, heart, and adipose tissue.
BG4KO mice had a greater than 99% reduction in brain GLUT4 protein levels relative to
WT, Lox, and Cre mice (Figure 2). Importantly, GLUT4 content in the heart, muscle, and
adipose tissue of BG4KO mice was expressed at similar levels to the littermate controls
(Figure 2), verifying brain specific GLUT4 knock-out.
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To determine if deletion of brain GLUT4 altered expression of other brain glucose
transporters, GLUT1 and GLUT3 protein expression were measured by Western blot.
No significant difference in whole brain GLUT1 and GLUT3 protein levels were
observed between BG4KO and littermate controls (Figure 3A,B). Furthermore, to
confirm brain insulin signaling was unaltered by brain GLUT4 deletion, insulin receptor
and pAKT protein were measured in the hypothalamus after a bolus IP insulin injection
(3U/kg). There were no significant differences in insulin receptor or insulin stimulated
pAKT protein expression between the groups (Figure 3C).

Effect of Brain GLUT4KO on energy and glucose homeostasis.
Body weight was measured weekly from 5 to 12 weeks of age. No significant
difference in body weight was observed between Cre and BG4KO mice (Figure 4A).
Intriguingly, both Cre and BG4KO mice had significantly reduced body weights
compared to WT and Lox mice (Figure 4A). No significant difference in body weight was
observed between WT and Lox mice (Figure 4). Thus, the expression of Cre itself
reduced body weight consistent with a previous report119.
The reduction in body weight was partly attributable to the reduction in body
length. Crown-rump body length was measured at 12 weeks of age and, consistent with
body weight, Cre and BG4KO were significantly shorter than WT and Lox mice (Figure
4B). Brain mass and perigonadal fat pad mass were not significantly different between
groups (Figure 4C).
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Brain GLUT4KO does not affect fasting or fed blood glucose levels, but results in
glucose intolerance.
To assess the effect of the brain GLUT4KO on whole-body glucose homeostasis,
fed and fasting glucose and insulin levels were measured in 12 week old mice on a
normal chow diet. Fasting and random fed glucose levels were similar in all groups
Figure 5A). Further, no difference in fasting or fed insulin levels were observed between
groups (Figure 5B).
To determine the role of brain GLUT4 in handling and responding to changes in
glucose, dynamic tests were performed in overnight fasted mice. In response to an
intraperitoneal glucose tolerance test (IPGTT; 2 mg/kg) BG4KO mice had significantly
higher glucose excursions during the GTT than WT, Lox, and Cre littermates (Figure
5C). To determine whether brain GLUT4 deletion also affected whole body insulin
sensitivity, insulin tolerance tests (ITT, 1 U/kg) were performed in BG4KO and control
mice. Despite the impaired glucose tolerance, BG4KO mice had similar reduction in
blood glucose in response to insulin compared to littermate controls (figure 5D). To
determine whether the impaired glucose tolerance in BG4KO mice was attributed to
altered glucose stimulated insulin secretion (GSIS), plasma insulin levels were
measured during the IPGTT. No difference in plasma insulin levels during the glucose
tolerance test (Figure 5E) and no difference in first phase insulin secretion (Figure 5F)
were observed between BG4KO mice and controls.
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BG4KO have reduced insulin sensitivity and hepatic insulin resistance
The effect of brain GLUT4KO on whole body insulin sensitivity was directly
assessed by hyperinsulinemic-euglycemic clamps in BG4KO mice and controls. For
statistical analyses, littermate control WT, Lox, and Cre mice were combined into one
control group (CON) since no statistically significant differences were observed between
these groups during the euglycemic clamp (e.g. glucose infusion rate, glucose kinetics,
hepatic glucose production). Blood glucose levels during the baseline period and during
the last hour of the clamp were not statistically different between BG4KO and CON
(Figure 6A). Basal and clamp insulin were also not significantly different between the
groups (data not shown). Interestingly, BG4KO mice required 22% lower glucose
infusion rate (34±3 versus 43±2 mg/kg/min; p<0.02) to maintain euglycemia compared
to controls, demonstrating whole-body insulin resistance (Figure 6B). Since BG4KO
mice had similar basal glucose disposal (Rd) and similar insulin-stimulated increase in
Rd as compared to CON mice, the defect in whole-body insulin sensitivity was not due
to changes in glucose disposal (Rd) (Figure 7A). Consistent with similar Rd values
between groups, no difference in tissue-specific glucose uptake in muscle or adipose
tissue was observed between BG4KO and CON mice (Figure 7B, C). However, the
ability of insulin to suppress endogenous glucose production (EGP) was only 48% in
BG4KO as compared to 79% in CON mice (Figure 8A, B, p<0.02). To test if insulin
resistance is due to impaired hepatic insulin signaling, phospho AKT (pAKT) and total
AKT (tAKT) protein expression were analyzed by Western blot following IP insulin. In
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response to insulin (3U/kg), hepatic pAKT protein expression increased similarly in
BG4KO and control mice (Figure 8C, D).
To determine whether deletion of GLUT4 in the brain results in altered glucose
uptake, brain glucose uptake was measured using a radioisotope glucose uptake assay
during a 2-hour hyperinsulinemic euglycemic clamp. Mean local rates of glucose uptake
were calculated according to Sokoloff’s equation110,111. Brain glucose uptake was lower
in BG4KO mice compared to control mice in select regions of the brain including the
ventromedial hypothalamus (VMH) and arcuate nucleus (ARC) (p<0.05 t-test) with a
trend for decreased uptake in the paraventricular nucleus (PVN), hippocampus,
cerebellum, nucleus tractus solitarus (NTS), and cortex (Figure 9A, B).

Role of central GLUT4 on the counterregulatory response to hypoglycemia
Pharmacological

inhibition

of

central

GLUT4

with

indinavir

attenuates

the

counterregulatory response to hypoglycemia
To test whether brain GLUT4 is important in the counterregulatory response to
hypoglycemia, indinavir (IDV), a GLUT4 inhibitor, or vehicle (artificial cerebrospinal fluid,
aCSF) was infused into the third ventricle (10 µg/min) of chronically cannulated rats
during a hyperinsulinemic hypoglycemic (~45 mg/dl) clamp. IDV is a pharmacologic
agent that has been shown to inhibit GLUT4 activity and glucose transport

114-116

. Blood

glucose was not different in the basal period or during the hyperinsulinemic clamp
period (Figure 10A). Further, no difference in epinephrine, norepinephrine, glucagon,
and corticosterone was observed in the basal period. Interestingly, during the clamp, the
glucose infusion rate required to maintain glucose at ~45 mg/dl was 44% higher in the
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IDV-treated rats compared to controls (Figure 10B, P<0.05). The higher glucose
infusion rates in IDV rats were associated with significantly attenuated counterregulatory
response in these animals. Specifically, third ventricle infusion of IDV resulted in a 24%
lower epinephrine response, a 22% lower norepinephrine response, and a 45% reduced
glucagon response to hypoglycemia compared to controls (Figure 10C,D,E).

Genetic deletion of brain GLUT4 impairs the counterregulatory response to
hypoglycemia
A genetic approach was used to further elucidate the role of brain GLUT4 in the
counterregulatory response to hypoglycemia. Hyperinsulinemic hypoglycemic (~30
mg/dl) clamps were performed in chronically cannulated, freely mobile BG4KO mice
and their littermate controls. Basal glucose levels were similar and glycemia was
carefully matched during the clamp period (Figure 11A). Insulin levels were also similar
in the basal and clamp conditions (Figure 11B). Despite matched glucose levels,
BG4KO mice required a lower glucose infusion rate to maintain ~30 mg/dl compared to
Cre controls (315+162 vs 611+125 AUC; p < 0.05 ANOVA). However, glucose infusion
rate was not statistically significantly different to WT and flox controls (data not shown).
Basal epinephrine levels were similar in all groups (Figure 11C). During hypoglycemia,
epinephrine levels rose similarly in the WT, Lox, and Cre mice (3133±600; 2902±560;
2633±355 pg/ml, respectively; P=NS). However, the epinephrine response in BG4KO
was significantly lower (1575±101 pg/ml) compared to littermate controls (P<0.05)
(Figure 11C). Further, glucagon response to hypoglycemia was significantly attenuated
in BG4KO mice (BG4KO 299±92 pg/ml; WT 650±57; Lox 597±74; Cre 651±39 pg/ml, p
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< 0.001) (Figure 11D). Norepinephrine and corticosterone responses to hypoglycemia
were not significantly different between the 4 groups (Figure 11E, F).

Impaired adrenomedullary response to stress is unique to hypoglycemia
To test if the reduced epinephrine response to hypoglycemia in BG4KO mice
was due to a generalized impairment in the adrenomedullary response to stress,
epinephrine levels were measured in BG4KO and control mice subjected to 60 min of
heat (42°C) stress. There was a significant increase in epinephrine and norepinephrine
levels induced by heat stress but the increment was similar in both groups of mice
(Figure 12A, B).

Brain

GLUT4KO

reduces

hypoglycemic-induced

neuronal

activation

in

the

paraventricular nucleus
To determine whether the impaired counterregulatory response in the BG4KO
mice was associated with impaired hypothalamic neuronal activation, c-fos activation in
response to hypoglycemia was measured in the hypothalamus following the
hyperinsulinemic hypoglycemic clamps. Despite matched levels and duration of
hypoglycemia, BG4KO mice had ~80% reduction in paraventricular nucleus (PVN) c-fos
positive cells compared to controls (BG4KO 28 ± 17 versus WT 120 ± 20, Lox 138 ±
19, Cre 141 ± 20 c-fos positive cells, p < 0.001) (Figures 13A, B).
To further test the role of brain GLUT4 glucose sensing in response to
hypoglycemia, whole body (zona-pellucida Cre driven) GLUT4 knockout mice
underwent hyperinsulinemic (120mU.kg-1.min-1) hypoglycemic (~35 mg/dl) clamps.
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Decreased neuronal activation during hypoglycemia was confirmed in these whole body
GLUT4 knockout mouse model. Whole body GLUT4 knockout mice that underwent 2
hours of hypoglycemia had reduced number of c-fos positive cells in the PVN (G4KO
67.6±18 vs WT 142.1±28; p<0.05) and VMH (G4KO 22.6±9 vs WT 53.1±4; p <0.05;
Figure 13C, D).

Brain GLUT4KO causes impaired neuronal glucose sensing
In order to test whether the observed impaired counterregulatory response to
insulin-induced hypoglycemia in BG4KO mice is a result of impaired brain glucose
sensing or impaired insulin action, changes in membrane potential and input resistance
of individual glucose inhibited (GI) neurons of the ventromedial hypothalamus (VMH)
were measured using whole-cell current clamp recordings in brain slices both in the
presence and absence of insulin. As expected for VMH GI neurons bathed in sufficient
2.5mM glucose, action potential frequency in this basal state was low in recordings from
control mice (0.43 +/- 0.12 Hz; N=14). Although, baseline action potential frequency
tended to be higher in recordings of VMH GI neurons from BG4KO mice (0.75+/0.22;
N=16) it did not reach statistical significance due to interneuron variation. On the other
hand, VMH GI neurons from BG4KO mice exhibited significantly higher baseline input
resistance (BG4KO: 1465+/-90M, N = 16; Control: 1042+/-77 M, N=14; P<0.01) and
a depolarized membrane potential compared to GI neurons from control mice (BG4KO:
-56+/-1mV; Control: -60+/-1mV; P<0.01). Increased excitability of VMH GI neurons in
the absence of Glut4 is consistent with reduced glucose uptake.
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The glucose sensitivity of VMH GI neurons from control and BG4KO mice is
illustrated by the whole cell current clamp recordings in figures 14A and 14B,
respectively. No group differences were observed in GI neurons in response to a
maximal glucose decrease from 2.5 to 0.1mM. In contrast, GI neurons from BG4KO
mice had a significantly (p<0.0001) impaired change in membrane potential and input
resistance (62% and 71% impairment, respectively) in response to a glucose decrease
from 2.5 to 0.5mM (Figures 14A-D) indicating BG4KO mice have impaired glucose
sensing.
To determine whether the effects of insulin on VMH GI neurons are mediated by
GLUT4, we evaluated the effects of 5nM insulin on the electrical properties of VMH GI
neurons from BG4KO and control mice. Interestingly, insulin reversed the excitatory
effects of 0.1mM glucose by decreasing input resistance and hyperpolarizing the
membrane potential of VMH GI neurons to a similar extent in both genotypes (BG4KO
% change: membrane potential -8+/-0.4, input resistance -14+/-0.7, n=7; control
%change: membrane potential -9+/- 0.6, input resistance -16+/-1, n = 8; P=NS between
genotypes) indicating insulin’s actions on these neurons is independent of GLUT4.
Particularly interesting was that the current-voltage relationships obtained in voltage
clamp indicate that the reversal potential for the effects of insulin and glucose were
significantly (p<0.05) different, with the effect of insulin reversing near the K + equilibrium
potential (-94+/-4mV, n =4; Keq -99mV) and the effect of glucose reversing near the Clequilibrium potential (-71+/-6, n=5; Cleq -60mV, figure 14E).
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Figure 2. Brain-specific deletion of GLUT4. (A) Whole brain, gastrocnemius muscle,
heart, and white adipose tissue (WAT) were harvested and homogenized for western
blot analysis of GLUT4. GLUT4 was markedly reduced in the brain of BG4KO mice
(BG4KO) compared to wild-type mice (WT), Lox expressing (Lox) and Cre expressing
(Cre) mice. GLUT4 protein levels in muscle, heart, and WAT were similar between
BG4KO and control mice. (B) Quantification of brain GLUT4 protein content. BG4KO
(black bar, n=11) had a greater than 99% reduction in brain GLUT4 levels compared to
WT (white bar, n=6), Lox (horizontal hash, n=6), and Cre (slanted hash, n=6). *p <
0.001 vs WT, Lox, and Cre mice. Data expressed as mean ± S.E.M.
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Figure 3. Brain GLUT1, GLUT3, pAKT, and insulin receptor protein expression
was not altered in neuronal GLUT4 KO mice. (A) Brain GLUT1 and (B) brain GLUT3
protein expression as measured by Western blot analysis was not different in brain
GLUT4KO mice (KO, black bar, n=5) versus wild-type (WT, white bar, n=4), Lox
(horizontal hash, n=4), and Cre (slanted hash, n=4). C) Hypothalamic phospho-AKT
(pAKT) and insulin receptor (IR ) protein expression were not different between
BG4KO (gel lanes 3 and 4, black bar) and control mice (Cre, gel lanes 1 and 2, white
bar) 30 minutes after an IP insulin (3U/kg) injection. Data expressed as mean ± S.E.M.
n=4-5 per group.
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Figure 4. Brain GLUT4 knock-out did not affect body weight. (A) Body weight was
similar between Cre (open triangle) mice and BG4KO (closed triangle) mice. Cre and
BG4KO mice had slightly lower body mass compared to WT (open circle) and Lox
(closed circle) mice. No difference in body weight was observed between WT and Lox
mice. n=10-20 mice per group. (B) The reduction in body weight was attributable to
smaller crown-rump length in Cre (slanted hash) and BG4KO (black bar) mice
compared to wild type (open bar) and Lox (horizontal hash) mice. (C) Brain mass, fat
pad mass, and heart weight were not significantly different between groups. n=5-7 mice
per group. *p < 0.05 vs. WT, Lox, and Cre. Data expressed as mean ± S.E.M.
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Figure 5. Normal blood glucose but impaired glucose tolerance in BG4KO mice.
(A) Male BG4KO (black bar) have similar fed and fasting blood glucose levels as well as
similar fed and fasting plasma insulin levels compared to wild-type (open bar), Lox
(horizontal hash), and Cre (slanted hashed). (B) BG4KO mice had similar fed and
fasting blood insulin levels compared to controls. (C) Intraperitoneal glucose tolerance
tests (IPGTT, 2 mg/kg) were performed in 12 week old male mice. BG4KO mice (closed
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triangles) had significantly higher excursions in blood glucose compared to WT (open
circles), Lox (closed circles), and Cre (open triangles) mice where indicated. (D) No
difference in the blood glucose was observed between BG4KO and control mice during
an insulin tolerance test. (E) Insulin secretion during a glucose tolerance test was
similar between BG4KO (closed triangle, n=4), wild-type (open circle, n=9), lox (closed
circle, n=4) and Cre mice (open triangle, n=4) (p=NS). (F) In a separate study, first
phase insulin secretion was measured during an intraperitoneal injection of glucose in
BG4KO (closed triangle, n=7) and Cre controls (open triangle, n=8). First phase insulin
secretion was not significantly different between groups. *p < 0.05 vs. WT, Lox, Cre.
Data expressed as mean ± S.E.M. n=6-17 mice per group.
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Figure 6. Euglycemic clamp glucose and glucose infusion rate. (A) Blood glucose
during a hyperinsulinemic euglycemic clamp. No difference in blood glucose before or
during the last hour of the clamp was observed between BG4KO (closed triangles) and
control mice (CON, open triangles). (B) Despite matched blood glucose levels, BG4KO
mice (closed triangles) required a significantly lower glucose infusion rate to maintain
euglycemia compared to CON (open triangles) indicating insulin resistance (*p < 0.05,
BG4KO vs. CON, all timepoints). Data expressed as mean ± S.E.M. n= 12-20 mice per
group. CON= WT, Flox, and Cre mice.
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Figure 7. Normal glucose disposal in BG4KO mice during a euglycemic clamp. (A)
Rate of whole body glucose disposal at baseline and during the last 30 minutes of the
hyperinsulinemic clamp was not significantly different between BG4KO (black bar) and
CON (open bar). (B and C)

14

C-2deoxyglucose determined glucose uptake specifically

in muscle (B) and adipose tissue (C) was similar between BG4KO (black bar, n=7) and
CON (white bar, n=17) during the hyperinsulinemic clamp. Data expressed as mean ±
S.E.M. n= 12-20 mice per group. CON= WT, Flox, and Cre mice. All data expressed as
mean ± S.E.M.
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Figure 8. Hepatic insulin resistance in BG4KO mice during a euglycemic clamp.
(A) Insulin suppressed endogenous glucose production (EGP) in BG4KO (black bar)
mice to a lesser degree as compared to CON mice (white bar) (BG4KO 12.3±2.3 vs
controls 5.1±2.3 mg/kg/min, *p < 0.04, ANOVA) B) Percent suppression of endogenous
glucose production was reduced in BG4KO mice compared to controls (BG4KO 48±8%
vs controls 79±8% suppression, *p < 0.02) during the last hour of the hyperinsulinemic
clamp. C) Hepatic expression of phospho-AKT (pAKT), total AKT (tAKT) and -actin as
shown by western blot after an IP bolus insulin (3U/kg) or saline injection. D)
Quantification of hepatic pAKT shows that in both control (CON) and BG4KO mice
hepatic pAKT increases in response to insulin (black bar) equally as compared to saline
(white bar) in both groups (n=3 per group). Data expressed as mean ± S.E.M. n= 12-20
mice per group. CON= WT, Flox, and Cre mice. All data expressed as mean ± S.E.M.
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Figure 9. Reduced brain glucose uptake in BG4KO mice. Brain glucose uptake was
measured using

14

C-2-deoxyglucose autoradiography in mice that underwent a

hyperinsulinemic euglycemic clamp. (A) Precise identification of the areas of interest
were accomplished by Nissl staining (left panels) and identifying the desired areas (i.e.
ventromedial hypothalamus, (VMH), red dashed oval outline) and arcuate nucleus (red
dashed triangular outline), and measuring the density of the outlined areas of interest on
the exposed autoradiographic films (right panels). (B) Quantification of brain glucose
uptake during euglycemia using Sokoloff’s equation in BG4KO (black bar, n=5) and
control mice (white bar, n=5). Brain glucose uptake during the hyperinsulinemic
euglycemic clamp was significantly reduced in BG4KO mice compared to control mice
in ventromedial hypothalamus (VMH) and arcuate nucleus (ARC) (*p < 0.05, t-test).
Data expressed mean ± S.E.M.
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Figure 10. Intracerebroventricular (ICV) infusion of an inhibitor of GLUT4
transport, indinavir, reduced the counterregulatory response to hypoglycemia.
Indinavir (IDV, closed circle, n=4) or artificial cerebrospinal fluid (aCSF, open circle,
n=9) was infused for 90 min before and for the duration of a 90 min hyperinsulinemic
hypoglycemic (~45 mg/dl) clamp in Sprague-Dawley rats. (A)

Blood glucose was

precisely matched between rats treated with ICV infusions of either IDV or aCSF. (B)
Despite matched blood glucose levels, IDV treated rats (closed circle) required a
significantly higher glucose infusion rate than control rats (open circle) (*p < 0.01, t-test
of all timepoints). The higher glucose infusion rate was attributed to the attenuated
counterregulatory response to hypoglycemia due to the reduced GLUT4-mediated
glucose sensing. Epinephrine (C), norepinephrine (D), and glucagon (E) response to
hypoglycemia was significantly reduced in IDV rats versus controls (* p<0.05 by ANOVA
for all hypoglycemic timepoints for epinephrine and norepinephrine, AUC for glucagon).
Data expressed mean ± S.E.M.
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Figure

11.

BG4KO

mice

have

impaired

counterregulatory

response

to

hypoglycemia. BG4KO and control mice were subjected to hyperinsulinemic
hypoglycemic (~30 mg/dl) clamps. (A) Blood glucose was not different before or during
the clamp between BG4KO (closed triangle, n=5), wild-type (open circle n=5), Lox
(closed circle, n=6), and Cre (open triangle, n=11). B) Insulin levels at basal and during
the hypoglycemic clamp were not different between the groups. Wild type (open bar),
Lox (horizontal hash), Cre (slanted hash) and BG4KO (black bar). (C and D)
Epinephrine (C) and glucagon (D) responses to hypoglycemia were significantly
reduced in BG4KO (black bar) mice compared to WT (open bar), Lox (horizontal hash),
and Cre (slanted hash). Norepinephrine (E) and corticosterone (F) levels during the
hypoglycemic clamp were similar in all groups. *p < 0.05 versus WT, Lox, and Cre. Data
expressed as mean ± S.E.M. n= 4-11 per group.
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Figure 12.

Normal sympathoadrenal response to heat stress in brain GLUT4

knock-out

mice.

Heat

stress

counterregulatory response

in

was

induced

to

BG4KO

mice

was

determine

if

specific for

the

impaired

hypoglycemia.

Norepinephrine (A) and epinephrine (B) levels increased during heat stress but there
was no difference between the control (white bar) or BG4KO mice (black bar). Data
expressed as mean ± S.E.M.
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Figure 13. Brain specific and whole body GLUT4 KO mice have impaired
hypothalamic neuronal activation during hypoglycemia. A and B) Nestin-Cre
GLUT4 KO mice (A) Representative c-fos immunostaining of the hypothalamic
paraventricular nucleus (PVN) in wild-type (WT) and BG4KO (KO) mice after 2 hours of
hypoglycemia. (B) Quantification of c-fos immunostaining. The number of c-fos positive
cells in the PVN was greatly reduced in BG4KO mice (black bar) compared to wild-type
(open bar), Lox (horizontal hash), and Cre (slanted hash). *p < 0.05 versus WT, Lox,
and Cre. n= 4-11 per group. C and D) Zona-Pellucida Cre GLUT4 KO mice (Whole body
GLUT4 KO) (C) Immunohistochemistry of brain sections from WT (left) and G4KO
(right) mice after 2 hours of a hypoglycemic clamp. C-fos positive staining is shown in
the paraventricular nucleus (PVN) and ventromedial hypothalamus (VMH) of WT and
G4KO mice. (D) Quantification of c-fos positive cells represented as total number per
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mouse. G4KO mice (black bar) had significantly less c-fos positive cells in the PVN and
VMH compared to WT mice (white bar). PVN: 68+18 vs. 142+28 (*p<0.04). VMH: 23+9
vs. 53+4 (*p<0.02). n=6/group. Data presented as mean+sem. 3V= third ventricle
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Figure 14. Impaired glucose sensing in VMH GI neurons from BG4KO mice. Whole
cell current clamp traces of VMH glucose-inhibited (GI) neurons in brain slices from
nestin-cre control (A) and BG4KO (B) mice. The upward deflections represent action
potentials, the resting membrane potential is given to the left of each trace, and the
downward deflections are the voltage response to a constant current pulse. As
compared to GI neurons from controls (white bars), GI neurons from BG4KO mice
(black bars) had markedly impaired changes in membrane potential (C) and input
resistance (D) when glucose levels were changed from 2.5 mM to 0.5 mM. E) Currentvoltage relationship for a VMH GI neuron from control mice. The reversal potential for
the effect of glucose (2.5 vs 0.1 mM glucose, upward dotted arrow) is close the
theoretical Cl- equilibrium potential (ECl ~ -60 mV) suggesting that glucose activates a
chloride channel. In contrast the reversal potential for the effect of insulin (0.1mM
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glucose vs 0.1mM glucose + 5 nM insulin, downward dashed arrow) is near the
theoretical K+ equilibrium potential (EK ~-99mV) suggesting that insulin activates a
potassium channel. *p < 0.001 versus control, data expressed as mean ± S.E.M. n=6-9
per group. Performed in collaboration with Dr. Vanessa Routh, New Jersey Medical
School.
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Discussion
Based on immunohistochemical studies that identified GLUT4 in discrete areas
of the central nervous system including the hypothalamus21, brain GLUT4 has been
suggested to have a role in neuronal glucose sensing and whole body energy
homeostasis. However, the physiological roles of central GLUT4 have remained
unknown. This current study demonstrated a novel role of brain GLUT4 in the
modulation of whole body glucose homeostasis, brain glucose sensing, and the
counterregulatory response to hypoglycemia.
Tissue specific deletion of brain GLUT4 was accomplished by Cre-Lox
technology. As expected, knockout of GLUT4 in the brain was virtually complete, while
GLUT4 protein expression was still expressed at normal levels in heart, adipose tissue,
and skeletal muscle. Further evidence for unaltered peripheral expression of GLUT4
was noted by similar rates of whole body, adipose, and skeletal muscle glucose uptake
in BG4KO and control mice during a hyperinsulinemic euglycemic clamp.
An interesting finding in this study was the expression of nestin-Cre alone
resulted in a slight reduction in body weight and crown-rump length, similar to previous
studies119,120, which may be attributed to Nestin-Cre’s mild hypopituitarism121. Since
both BG4KO and nestin-Cre- mice express Cre+, the lack of difference in body weight
between these two Cre+ groups indicate that deletion of brain GLUT4 did not have an
effect on overall body weight. In consideration of this effect of nestin-Cre expression, all
experiments were compared to Cre+/- littermates as a control group. Notably though,
WT, lox, and Cre mice had similar metabolic phenotypes with regard to all other
metabolic parameters assessed such as blood glucose levels, insulin levels, glucose
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tolerance, insulin sensitivity, and counterregulatory responses. Thus, although nestinCre expression resulted in a smaller size, it did not affect any other measured metabolic
phenotype parameters. Importantly, a pharmacologic approach using indinavir to inhibit
brain GLUT4 glucose transport during hypoglycemia produced similar results as the
genetic approach indicating brain GLUT4 is important in brain glucose sensing.
Consistent with a critical role for GLUT4 in mediating brain glucose sensing, the whole
body G4KO mice, recently generated in the Kahn laboratory, also showed impaired
neuronal activation in response to hypoglycemia.
Fasting and fed glucose levels were similar in BG4KO and control mice,
suggesting little contribution of brain GLUT4 in regulating basal glucose homeostasis.
When challenged with a glucose load during an IP glucose tolerance test, BG4KO mice
had significantly higher blood glucose excursion than control mice indicating glucose
intolerance. Consistent findings of glucose intolerance have recently been reported in a
distinct GLUT4 neuron ablation mouse model (Ren and Accili, Diabetes Suppl.1, A6,
2011). Dynamic insulin tolerance tests, showed no difference in blood glucose lowering
effect of insulin between BG4KO and control mice. The impaired glucose tolerance, but
seemingly normal insulin sensitivity, could be attributed to diminished insulin secretion.
However, glucose-stimulated insulin secretion was measured and no difference in
insulin levels was seen between BG4KO and control mice after a glucose challenge.
Thus, pancreatic β-cell responses to glucose remained unaffected by brain GLUT4
deletion.
An insulin tolerance test is an imprecise measure of insulin sensitivity because
with

falling blood

glucose

levels, differential counterregulatory responses to
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hypoglycemia (specifically an attenuated counterregulatory response) may mask the
degree of insulin resistance. To directly assess insulin sensitivity, hyperinsulinemiceuglycemic clamps were performed in BG4KO and control mice. BG4KO mice required
a significantly lower glucose infusion rate to maintain euglycemia than controls,
indicating insulin resistance. To better define the exact nature of the insulin resistance,
glucose fluxes and glucose uptake into specific tissues were measured during the
euglycemic clamp. Consistent with normal GLUT4 expression in peripheral tissues,
BG4KO mice had a similar rate of glucose disposal as control mice. Further, glucose
uptake in skeletal muscle and adipose tissue was not different between BG4KO and
control mice. The insulin resistance in BG4KO mice can be attributed to hepatic insulin
resistance as noted by the impaired ability of insulin to suppress endogenous glucose
production. Since insulin stimulated AKT phosphorylation in the liver was found to be
normal in BG4KO mice, hepatic insulin resistance in BG4KO mice seems to be
independent of direct insulin signaling in the liver and is likely mediated via indirect
mechanisms. Potential indirect roles of altered suppression of plasma free fatty acid
levels in indirectly regulating EGP122 could not be determined as free fatty acids were
not measured in this current study. Recent studies have demonstrated a role for central
insulin signaling as an indirect mechanism by which insulin acts to suppress EGP,
possibly via efferent vagal and sympathetic actions123,124. The absence of brain GLUT4
in BG4KO mice may have limited the central actions of insulin to indirectly suppress
EGP; although this is not due to proximal defects in hypothalamic insulin signaling as
this study demonstrates hypothalamic insulin signaling is preserved in BG4KO mice,
both in vivo and in vitro. One explanation for hepatic insulin resistance in BG4KO mice
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may be that chronic adaptations in BG4KO mice led to altered neuronal development
and plasticity altering the neuronal circuitry involved in glucose homeostasis125.
Alternatively, reduced centrally mediated insulin inhibition of glucagon secretion may
lead to a failure to suppress hepatic glucose production compared to controls126.
Although glucagon was not measured during the euglycemic clamp, impaired regulation
of glucagon secretion in the BG4KO mice was noted in the hypoglycemia studies.
Regardless of the mechanism, the results indicate that insulin acts to regulate hepatic
glucose production, at least in part, through brain GLUT4.
Several studies have suggested a relationship between central insulin action and
GLUT416,21,127. When experimental conditions of hyperinsulinemia were studied that
could maximize the potential difference in brain glucose uptake between BG4KO and
control mice, brain glucose uptake into regions that normally express relatively high
levels of GLUT4 was reduced in BG4KO mice. The reduced brain glucose uptake in
BG4KO mice was expected to be relatively small because GLUT4 is normally
expressed at a low level and only expressed in a fraction of all neurons16. Although
recent studies have shown insulin-stimulated GLUT4 translocation occurs in
neurons22,114,128 the current in vivo techniques are not of sufficient detail to resolve
individual neuron glucose uptake. Further in vitro studies from neurons of BG4KO mice
are needed to assess the role of GLUT4 neuron specific glucose uptake.
As GLUT4 and insulin receptors are co-expressed in up to 75% of glucose
sensing neurons in the VMH16, brain GLUT4 may have an important role in the ability of
neurons to sense and respond to changes in glucose. To test this possibility, the
counterregulatory response to hypoglycemia was assessed in rodents that had central
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GLUT4 inhibited pharmacologically (by indinavir) or genetically (BG4KO mice). Indinavir
has been shown to selectively inhibit glucose transport through GLUT4 in both cell
culture and in brain slices114-116. Both pharmacological inhibition as well as genetic
deletion of central GLUT4 resulted in impaired epinephrine response as well as an
attenuated glucagon response to hypoglycemia. Acute pharmacological inhibition of
CNS GLUT4 was associated with a blunted counterregulatory response, demonstrated
by an appropriately elevated glucose infusion rate during the hypoglycemic clamp.
However, the paradoxically low glucose infusion rates in the BG4KO mice were likely
due to their insulin resistance. Interestingly, since streptozotocin diabetic rats have
reduced brain GLUT4 expression103 and impaired epinephrine and glucagon responses
to hypoglycemia129, it may be that the impaired counterregulatory response to
hypoglycemia associated with insulin deficient diabetes is mediated, at least in part, by
decreased brain GLUT4.
To determine whether this impaired counterregulatory response was unique to
hypoglycemia or a result of a more global impairment in the sympathoadrenal response
to general stress, BG4KO and control mice were subjected to heat stress. The
adrenomedullary responses to heat stress were identical in BG4KO and control mice
indicating that BG4KO mice have an intact sympathoadrenal response to stress and
that the impaired counterregulatory response in BG4KO is unique to hypoglycemic
stress.
To determine whether the impaired counterregulatory response to hypoglycemia
in the BG4KO mice was associated with impaired neuronal activation, c-fos staining
was quantified in hypothalamic PVN of mice that underwent a hyperinsulinemic
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hypoglycemic clamp130. In response to hypoglycemia, c-fos expression increased
predominantly in the PVN, consistent with previous studies131. Notably, PVN c-fos
activation to hypoglycemia was significantly reduced in BG4KO mice compared to
controls. This finding of impaired c-fos activation in the PVN in response to
hypoglycemia was independently confirmed in another whole body (including the brain)
GLUT4 knockout model in which there was impaired neuronal activation in the PVN and
VMH in response to hypoglycemia. The impaired hypoglycemia-induced c-fos activation
in the brains of both of these GLUT4 knockout mouse models could represent reduced
glucose sensing of PVN neurons or, given that the PVN receives input from other
glucose sensing neurons in other regions of the brain, could represent an indirect
reduction in afferent inputs from other brain regions. In either case, the brains of GLUT4
knockout mice have a profound impairment in c-fos activation, consistent with other
models of impaired glucose sensing and impaired counterregulation 130. To more
specifically identify the role of brain GLUT4 in glucose sensing within ventromedial
hypothalamic neurons, electrophysiological studies were performed. GI neurons from
the VMH of BG4KO mice have an impaired response to decreasing glucose
concentrations as measured by whole-cell clamp recordings thus supporting the
findings that BG4KO mice have impaired hypothalamic glucose sensing.
The simultaneous attainment of hyperinsulinemia and hypoglycemia with the
hyperinsulinemic clamp studies do not allow us to determine whether reduced brain
glucose sensing/uptake in the BG4KO mice is due to the absence of the acutely
induced insulin-mediated neuronal GLUT4 translocation or reduced glucose transport
due to the chronic absence of GLUT4, however our electrophysiology data support the
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latter. First, in the absence of insulin, the finding of enhanced baseline excitability of
VMH GI neurons from BG4KO mice is consistent with reduced intracellular glucose.
Secondly, the addition of insulin equally inhibited VMH GI neurons from control and
BG4KO mice. Finally, the current-voltage relationships indicate that insulin did not lead
to activation of a Cl- channel as would be expected if insulin increased glucose
uptake132. Interestingly, while insulin has been shown to inhibit hypothalamic AMPK 133,
this is unlikely to explain insulin’s effects on GI neurons because AMPK inhibition
stimulates GI neurons by closing a Cl- channel134. Rather, the inhibitory effect of insulin
on VMH GI neurons resulted from activation of a K+ channel. This insulin sensitive K+
channel is possibly the ATP-sensitive K+ channel since insulin has been reported to
activate this channel in other hypothalamic glucose sensing neurons 135,136. These data
thus suggest that insulin inhibits GI neurons through a Glut4/glucose independent
activation of a K+ channel.
It has previously been reported that neuronal insulin receptor knock-out (NIRKO)
mice have a reduced content of brain GLUT4, and similar to the current BG4KO mice,
NIRKO mice also demonstrate 1) glucose intolerance, 2) mild insulin resistance, 3)
impaired epinephrine responses to hypoglycemia, 4) impaired neuronal activation to
hypoglycemia, and 5) impaired glucose sensing in GI neurons of the VMH 27,105,106. The
similarities in the phenotype of NIRKO and BG4KO mice suggest that many of the
actions of insulin in the brain are mediated by GLUT4. Paradoxically though, the current
study demonstrates that hypothalamic insulin signaling was unaltered by GLUT4
deletion and acute electrophysiological responses to insulin administration are
independent of GLUT4. Collectively, it is hypothesized that the chronic lack of insulin
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signaling or GLUT4 in the brains of NIRKO or BG4KO mice, respectively, that leads to
the observed impairments in neuronal glucose sensing appears to be mechanistically
distinct from the acute actions of insulin and/or GLUT4 translocation in regulating
neuronal glucose sensing and the counterregulatory response to hypoglycemia.
As GLUT4 is expressed in diverse regions of the brain, BG4KO mice will be a
useful tool in elucidating other potential roles of brain GLUT4 in cognition, learning and
memory, and balance and coordination. In conclusion, central nervous system GLUT4
plays an important role in regulating whole body glucose homeostasis, brain glucose
sensing, and the counterregulatory response to hypoglycemia.
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Chapter 3. Antecedent Glycemic Control Reduces Severe Hypoglycemia-Induced
Neuronal Damage in Diabetic Rats
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Abstract
Brain damage due to severe hypoglycemia occurs in insulin treated people with
diabetes. This study tests the hypothesis that chronic insulin therapy that normalizes
elevated blood glucose in diabetic rats would be neuroprotective against brain damage
induced by an acute episode of severe hypoglycemia. Male Sprague-Dawley rats were
split into 3 groups, 1) control, non-diabetic, 2) STZ-diabetic, and 3) insulin treated STZdiabetic.

After

3

weeks

of

chronic

treatment,

all

rats

underwent

acute

hyperinsulinemic/severe hypoglycemic (10-15 mg/dl) clamps for 1 hour. Rats were
subsequently analyzed for brain damage and cognitive function. Severe hypoglycemiainduced 15-fold more neuronal damage in diabetic rats as compared to non-diabetic
rats. Chronic insulin treatment of diabetic rats, that nearly normalized glucose levels,
markedly reduced neuronal damage induced by severe hypoglycemia. Fortunately, no
cognitive defects associated with the hypoglycemia-induced brain damage were
observed in any group. In conclusion, antecedent blood glucose control represents a
major

modifiable

therapeutic

intervention

that

can

afford

neuroprotection against severe hypoglycemia-induced brain damage.
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Introduction
Severe hypoglycemia is a side effect of insulin therapy affecting ~40% of insulin
treated diabetics29. Insulin treated diabetic patients experience an average of two
symptomatic hypoglycemic episodes per week while severe hypoglycemia is
experienced approximately once a year29. By depriving the brain of glucose, severe
hypoglycemia can lead to brain damage. The cortex and hippocampus are especially
sensitive to the brain damaging effects of severe hypoglycemia61. Deficits in learning
and memory have been shown to be a direct consequence of severe hypoglycemiainduced hippocampal neuronal damage51,53,54. Clinical research has shown that severe
hypoglycemia induces cognitive deficits in some7,8,55,56 but not all studies57-59. Animal
studies have shown that rats exposed to severe hypoglycemia perform worse in a
Morris water maze60 indicating that brain damage is functionally related to poorer
cognitive performance. Since uncontrolled diabetes magnifies the extent of severe
hypoglycemia-induced brain damage61, it was hypothesized that chronic hyperglycemia
associated with chronic insulin deficiency induces a mal-adaptive process that
predisposes the brain to more extensive hypoglycemia-induced damage. Insulin has
been shown to protect against ischemia-induced neuronal death both in vitro64 and in
vivo67, but the potential neuroprotective effects of long-term insulin therapy for diabetic
animals have yet to be examined in response to severe hypoglycemia induced brain
damage.
The aim of this study was therefore to determine if chronic insulin therapy
resulting in the near normalization of glycemia could protect diabetic rats from
hippocampal and cortical brain damage induced by a single episode of severe
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hypoglycemia. It was also determined if this neuroprotective effect would also safeguard
against hypoglycemia-induced deficits in learning and memory.

Methods
Animals and Surgery. Nine-week-old male Sprague-Dawley rats (Charles River
Laboratories) were housed individually in temperature- and light-controlled environments
fed ad libitum. All studies were done in accordance with and approved by the Animal
Studies Committee at Washington University School of Medicine. In rats destined to
undergo severe hypoglycemia, indwelling catheters were implanted under anesthesia in
the left carotid artery and right jugular vein, as previously described61. In control rats not
destined to undergo hypoglycemia, the left carotid artery and right jugular vein were
ligated under anesthesia.

Induction of diabetes. Three days post-surgery, rats received intraperitoneal injections
of either streptozotocin (STZ; 65 mg/kg, n = 37; Sigma) to induce diabetes or vehicle 0.1
mM sodium citrate (Fisher Scientific) buffer for non-diabetic controls (CON, n = 18)
(Figure 15). Some rats were injected a second time with STZ to ensure random glucose
>300 mg/dl (Ascensia Contour BG monitors, Bayer HealthCare, Mishawaka, IN).
(Figure 16A)

Insulin treatment. Eighteen of the diabetic rats were treated with subcutaneous insulin
pellets (STZ+Ins; Linplant, ~2U/day, Lin Shin, Toronto, ON, Canada) to achieve blood
glucose levels <250 mg/dl. If these rats were noted to have tail vein blood glucose >250
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mg/dl, insulin (Lantus, 0-2.5U/day; sanofi-aventis, Bridgewater, NJ) was injected
subcutaneously once daily. If blood glucose values were below 50 mg/dl for 3 or more
days, rats were excluded from the study.

Hyperinsulinemic hypoglycemic clamp. Three weeks after STZ or vehicle injections,
hyperinsulinemic (0.2 U·kg–1·min–1) hypoglycemic (10-15 mg/dl) clamps were performed
in non-diabetic CON, uncontrolled STZ-diabetic, and chronically insulin treated STZ
rats, as previously described60,61. At the start of insulin (Humulin R; Eli Lilly, Indianapolis,
IN) infusion, all clamped rats received intravenous glucose (50% dextrose; Hospira,
Lake Forest, IL) to match the rate of glucose decline observed in diabetic rats. All
groups were precisely matched for duration (1 hour) and depth of hypoglycemia (10–15
mg/dl). After 1 hour of severe hypoglycemia, insulin infusion was discontinued, and
glucose was given to end hypoglycemia. Rats subjected to severe hypoglycemia were
examined either for brain damage or behavioral testing (Figure 15).

Fluoro-Jade B and hematoxylin-eosin staining. One week after the severe
hypoglycemic clamps, anesthetized rats were intracardially perfused with 0.01 mol/l
PBS (Sigma) followed by 4% paraformaldehyde (Electron Microscopy Sciences,
Hatfield, PA)60,61. Brains were immersed in 4% paraformaldehyde overnight and then
cryoprotected in 30% sucrose. Beginning at 2.8 mm posterior to the bregma, four
coronal cryostat sections (20 m), 120 m apart, were analyzed for neuronal damage
by Fluoro-Jade B (Chemicon International) and hematoxylin-eosin (H-E) (Sigma)
staining. Fluoro-Jade B is a well-characterized stain for degenerating neurons and was
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performed as described by Schmued and Hopkins137. Fluorescent cells (Fluoro-Jade–
positive cells) were quantified in both hemispheres of the cortex and of the hippocampal
structures CA1 and dentate gyrus. For each region of interest, data are expressed as
the average number of Fluoro-Jade B positive (FJB+) cells per section.

Behavioral testing. Consistent with other protocol designs52,54,138, histopathological
outcomes were assessed 1 week following the hypoglycemic neuronal insult, while
cognitive studies were performed 6–8 weeks later in a separate group of similarly
treated rats. This later assessment of cognitive function is a more useful measure of
clinical outcome and a better functional index of neuroprotection because it allows for a
complete and integrated evaluation of ongoing damage and possible recovery 139. After
a 6- to 8-week recovery from the severe hypoglycemic clamp, CON (n=12), STZ (n=11),
and STZ+Ins (n=12) rats, as well as a fourth group of sham operated negative control
diabetic rats not subjected to hypoglycemia (STZ No Hypoglycemia, STZ-NH, n=10)
were evaluated on a 1-hour locomotor activity test, a battery of sensorimotor measures,
and on the Morris water maze (MWM) task60.
One-hour locomotor activity test and sensorimotor battery. General locomotor
activity and exploratory behavior were evaluated for 1 h in an open field (41 x 41 x 38.5
cm

high)

constructed

of

Pleixglas

and

containing

computerized

photobeam

instrumentation consisting of a 16 x16 matrix of photocell pairs (MotorMonitor; Kinder
Scientific) to quantify ambulations (whole body movements) and vertical rearing
frequency. As previously described140, the ledge, platform, 90o-inclined screen, and
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walking initiation tests were conducted to measure balance, strength, coordination, and
initiation of movement.
Cognitive testing in the Morris water maze:

Spatial learning and memory were

assessed for CON (n=12), STZ (n=11), STZ+Ins (n=12), and STZ-NH (n=10) groups
using the Morris water maze test similarly to previously published methods 140. Cued
(visible platform, variable location) and place (submerged, hidden platform, constant
location) trials were conducted to train rats to navigate to a submerged platform (1.5 cm
below the surface of opaque water) in a round pool (118 cm diameter). A computerized
tracking system (ANY-maze, Stoelting Co., Wood Dale, IL) was used to quantify escape
path length, latency, and swimming speeds which served as dependent variables. Rats
first received cued trials to determine if non-associative dysfunctions (sensorimotor or
visual disturbances or alterations in motivation) were likely to affect performance in
subsequent place trials. The cued condition involved conducting two sessions of three
trials each (60-s maximum/trial) per day for two consecutive days during which the rats
were trained to swim to the submerged platform marked (cued) by a visible pole with 3 h
intervening between sessions. The data were analyzed in blocks of three trials each for
a total of four blocks. Three days later, the spatial learning capabilities of the rats were
tested using the place condition in the water maze. This is a reference-memory based
task where the rats were trained to learn the position of a submerged and hidden (since
pole is removed) platform, which remained in the same location across all trials. The
place trials protocol involved conducting two sessions of 3 trials each (60-s
maximum/trial) per day for five consecutive days using a 3-h interval between sessions.
The data were analyzed in blocks of six trials each (two daily sessions) for a total of 5
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blocks. On days 3 and 5, a probe trial was conducted 1 h after the last place trial which
involved removing the platform from the pool and quantifying the rats' search behaviors
in the four pool quadrants for 30 s to evaluate retention of the platform location. Probe
trial performance variables included: the number of times a rat passed directly over the
platform location (platform crossings); the time spent in the target quadrant; and spatial
bias which involved comparing the time spent in the target quadrant with time spent in
each of the other quadrants.

Statistics. All data are represented as means + sem. Data were analyzed by one-way
or repeated measures analysis of variance (ANOVA and rmANOVA, respectively). The
spatial learning data were analyzed using an ANOVA model containing one betweensubjects variable (Treatment: CON; STZ; STZ+Ins; and STZ-NH) and one withinsubjects (repeated measures) variable such as Blocks of Trials. For rmANOVAs, the
Huynh-Feldt correction was used for all within-subjects effects containing more than two
levels to help protect against violations of sphericity/compound symmetry assumptions
underlying the rmANOVA model. In addition, Bonferroni correction was used to help
maintain prescribed alpha levels (e.g., 0.05) when multiple comparisons were
conducted.

Results
Chronic insulin treatment nearly normalizes glucose level of diabetic rats. Rats
that received streptozotocin displayed elevated blood glucose levels two days post
injection and remained diabetic throughout the experiment compared to non-diabetic
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controls (CON 100+1 mg/dl vs. STZ 484+10 mg/dl; Figure 16A). Insulin treatment
reduced blood glucose levels to near normal (STZ+Ins 160+11 mg/dl). Sham operated
diabetic rats that did not undergo severe hypoglycemia (STZ-NH) had similar glucose
levels as the STZ group (STZ-NH 467+12 mg/dl). Prior to randomization, body weight
did not differ between groups (CON: 302+10, STZ: 308+5; STZ+Ins: 302+7; STZ-NH:
310+9g; Figure 16B). On the day of the severe hypoglycemic clamp, the non-diabetic
and insulin-treated diabetic rats had an increase in body weight to 408+37 and
387+14g, respectively, but 3 weeks of uncontrolled diabetes in the STZ and STZ-NH
rats resulted in a failure to increase body weight (329+22 and 339+10g, respectively,
p=NS compared to pretreatment; Figure 16B).

Hyperinsulinemic-hypoglycemic clamp. All rats experienced the same degree of
severe hypoglycemia (CON 12+0.3 mg/dl, STZ 13+0.7 mg/dl, STZ+Ins 12+0.3 mg/dl;
Figure 17A). During severe hypoglycemia, animals lost their righting reflex, displayed
seizure-like activity, and became minimally responsive. After one hour of severe
hypoglycemia, glucose reperfusion was started so that animals reached euglycemia
within 30 minutes (CON 159+48 mg/dl, STZ 181+31 mg/dl, STZ+Ins 172+48 mg/dl).
Almost immediately animals regained consciousness and their righting reflex and
seizure-like activity ceased. The animals were allowed to recover for 4 hours and then
returned to their cages. The following day blood glucose levels were back to their
respective values (CON 101+6 mg/dl, STZ 418+49 mg/dl, STZ+Ins 82+13 mg/dl).
Overall mortality associated with the episode of severe hypoglycemia was 29%.
Control rats had a mortality of 22% while STZ and STZ+Ins rats tended to have

68

increased mortality to 36% and 42%, respectively, but this did not reach significance
(p<0.25, Fisher exact test, Freeman Halton extension; Figure 17B).

Chronic insulin treatment decreases severe hypoglycemia-induced brain damage.
One week following the acute severe hypoglycemic episode, rats were sacrificed and
brains sectioned for neuronal damage using the marker Flouro-jade B which stains for
degenerating neurons. In spite of equal depth and duration of hypoglycemia, diabetic
rats had markedly increased (15-fold) brain damage in the hippocampus and cortex
compared to non-diabetic rats (Figure 18A,B). In particular in the hippocampus, the
CA1, CA3, and dentate gyrus regions had a 5-fold, 15-fold, and 45-fold increase in
damage, respectively. Chronic antecedent insulin treatment reduced neuronal damage
in diabetic rats (STZ+INS) in all regions to levels not significantly different from that of
non-diabetic rats (Figure 18A,B).

Severe hypoglycemia does not disrupt behavior. Severe hypoglycemia did not
significantly impair locomotor or sensorimotor functions (Figure 19A,B) when tested 6-8
weeks post-treatment (severe hypoglycemic clamp). An rmANOVA did not reveal any
significant effects involving treatment on total ambulations (whole body movements)
measured during the 1-hour locomotor activity test (Figure 19A) nor were any
differences observed in vertical rearing frequency (not shown). Similarly, no
performance differences between treatment groups were observed with regard to any
measure on the battery of sensorimotor tests. For example, although the CON group
tended to perform not as well as the diabetic groups in terms of being able to remain on
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a small elevated platform, a one-way ANOVA showed no significant differences among
groups on this sensorimotor test (Figure 19B) nor on other sensorimotor measures of
balance (ledge), strength (90º inclined screen) or initiation of movement (walking
initiation) out of a small delineated space (not shown).
Interestingly, we also found no general performance differences between
treatment groups on the learning and memory indices quantified during testing in the
Morris water maze. Specifically, no effects involving treatment were found following
rmANOVAs conducted on the escape path length (Figure 19C), latency, or swimming
speed data (not shown) during the cued (visible platform location) trials. These results
suggest that there were no visual, sensorimotor, or motivational disturbances in any of
the groups that would compromise swimming performance and thus confound
interpretation of the subsequent place trials data. With regard to the acquisition (spatial
learning) performance of the treatment groups during the place trials (Figure 19D), an
rmANOVA conducted on the path length data yielded a significant Treatment by Blocks
of Trials interaction, (F12,64 = 2.54; p=0.011). Subsequent comparisons showed that this
was mostly due to increased path length in the STZ NH group versus the STZ-Ins
(p=0.036) or the CON (p=0.037) groups during the first block of trials only, but not
thereafter. A significant Treatment by Blocks of Trials interaction (F12,64 = 2.32; p=0.016)
was also found for escape latency (not shown), although only the comparison between
the STZ NH versus STZ+Ins groups were significantly different ( p=0.017). Note that
although the comparisons cited here for block 1 revealed certain large (p<0.05)
differences between treatment groups, none of the “P” values were less than the
Bonferroni corrected level (p=0.05/4= 0.0125). Thus, it is appropriate to conclude that
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the performance of the treatment groups did not differ at any time with regard to path
length or latency during acquisition (place trials). Consistent with the general lack of
differences between treatment groups during the place trials were comparable
performance levels observed among groups during the probe trials. For example, oneway ANOVAs revealed non-significant treatment effects with regard to time in the target
quadrant during probe trial 1 (mid-acquisition) (Figure 19F) and platform crossings (not
shown). In addition, all groups demonstrated significant spatial bias for the target
quadrant that had contained the hidden platform as evidenced by each group spending
significantly more time in the target quadrant compared to times spent in each of the
other quadrants (p<0.01). Similar results were found for the same variables during the
second probe trial conducted 1 hour after the last place trial on day 5 (not shown).
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Figure 15. Experimental protocol for analysis of brain damage and cognitive
function after severe hypoglycemia. After recovery from arterial and venous
cannulation, rats were injected with streptozotocin (STZ) or vehicle (Con, n=18). Three
days later insulin treatment was started in a subset of the STZ diabetic rats (STZ+Ins,
n=15) by implanting an insulin pellet and starting insulin injections as needed to
maintain blood glucose <250 mg/dl. About 3 weeks later, hyperinsulinemic (0.2 U·kg–
1

·min–1) severe hypoglycemic (10-15 mg/dl) clamps were performed in all rats except a

group of diabetic rats that were not subjected to the severe hypoglycemic clamp (STZNH). After the episode of severe hypoglycemia, either neuronal damage was assessed
by Flouro jade B and H&E staining one week later, or rats were studied 6-8 weeks later
with sensorimotor and cognitive testing. Brain damage study: CON (n=6), STZ (n=6),
STZ+Ins (n=6); Cognitive testing study: CON (n=12), STZ (n=13), STZ+Ins (n=12),
STZ-NH (n=10)
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Figure 16. Glucose levels and body weight during the brain damage and cognitive
testing protocols. A) Blood glucose levels throughout the experiment. The nondiabetic (CON, closed circle) rats had glucose levels of ~100 mg/dl. After STZ injection,
STZ diabetic rats (open circle) and STZ diabetic rats no hypoglycemia(NH, open
triangle) had glucose levels of >450 mg/dl. The diabetic rats chronically treated with
insulin (STZ+Ins, closed triangle) group had markedly improved blood glucose levels
(160 + 11 mg/dl) throughout the experimental timeline. HYPO= day of severe
hypoglycemic clamp B) The non-diabetic (CON) and insulin treated diabetic (STZ+Ins)
groups increased their body weight over time while the STZ and STZ-NH groups did not
increase their body weight. Note: Time axis not to scale. Wk= week; n= 10-18 per
group. Data shown as mean + SEM.
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Figure 17. Severe hypoglycemic clamp glucose and mortality. A) Glucose levels
during the hyperinsulinemic/hypoglycemic clamp. Insulin infusion decreased glucose
levels over a 4 hour period in the CON (n=18), STZ (n=19), and STZ+Ins (n=18) groups
until glucose reached 15 mg/dl. Glucose was clamped between 10-15 mg/dl for 1 hour
and then hypoglycemia was terminated with increased glucose infusion throughout a 4
hour recovery period. B) Mortality associated with severe hypoglycemia was 22% in
CON, 36% in STZ, and 42% in STZ+Ins treated rats but the difference was not
significant (p<0.25). Note: Time axis not to scale.
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Figure 18. Severe hypoglycemia induced brain damage. A) Representative FluoroJade B (top 3 rows) and hematoxylin and eosin (H&E –bottom 3 rows) staining of the
cortex and hippocampal structures, CA1, CA3 and the dentate gyrus (DG), one week
following an episode of severe hypoglycemis in non-diabetic (CON), uncontrolled STZdiabetic (STZ), and chronically insulin treated STZ (STZ+Ins) rats. Neuronal damage is
indicated with Fluoro-Jade B positive cells (green fluorescence) or by pyknotic cells
(H&E staining, black arrows). Blue= dapi, nuclear stain. B) Brain damage was markedly
elevated in the cortex and hippocampus in STZ (white bar) rats compared to controls
(black bar). STZ+Ins (diagonal hash bar) reduced this damage in both regions. (*p<
0.05 ANOVA n=6 per group). Data shown as mean + SEM.
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Figure 19. Severe hypoglycemia does not produce impairment in behavioral and
cognitive functions. A) There were no significant effects involving treatment (severe
hypoglycemia) on general activity as measured by total ambulations (whole body
movements) during a 1-h locomotor activity test. B) Although the CON group tended to
perform not as well as the diabetic groups in terms of being able to remain on a small
elevated platform, there was no significant differences among groups on this
sensorimotor test. C) Groups did not differ in escape path length during the cued (visible
platform location) trials. D) A rmANOVA conducted on the path length data during the
place (spatial learning) trials yielded a significant Group (Treatment) by Blocks of Trials
interaction, (*p=0.011). This was mostly due to increased path length in the STZ NH
group versus the STZ-Ins (†p=0.036) or the CON (††p=0.0369) groups during the first
block of trials only, but not thereafter. E) No differences among groups were observed in
swimming speeds during the place trials. F) Groups performed similarly in terms of time
in the target quadrant during probe trial 1 (mid-acquisition). In addition, all groups
demonstrated significant spatial bias for the target quadrant that had contained the
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hidden platform as evidenced by each group spending significantly more time in the
target quadrant compared to times spent in each of the other quadrants (*p<0.01).
TGT= target quadrant, LFT= left quadrant, OPP= opposite quadrant, RGT= right
quadrant; Performed in collaboration with Dr. David Wozniak, Washington University in
St. Louis.
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Discussion
Studies investigating the potential neuroprotective role of insulin often do not
differentiate the acute versus chronic effects of insulin therapy. The present findings
show that while acute insulin-induced hypoglycemia can cause brain damage, chronic
insulin treatment in diabetic rats to restore normoglycemia is markedly neuroprotective
and significantly reduces the extent of severe hypoglycemia-induced brain damage.
It was hypothesized that the uncontrolled diabetic rats that displayed markedly
elevated hypoglycemia-induced brain damage would perform much worse than other
rats tested, and that the marked neuroprotective effects of chronic insulin therapy would
mitigate against demonstrable deficits in cognitive performance. As with clinical studies,
animal studies of hypoglycemia and cognitive performances are variable. However, it
was somewhat surprising that Morris maze testing was unable to demonstrate
differences in cognitive performances between the groups. Our previous Morris maze
studies in normal rats60 showed rapid improvements in escape path lengths and
latencies in sequential trial tests, very similar to the currently tested groups of rats,
suggesting that all of the current groups of rats performed equally well with no
detectable cognitive deficit. It is suspected that the extent of brain damage achieved in
the current studies did not reach a high enough threshold to cause demonstrable
deficits in learning/memory performances as determined by Morris maze testing.
Previous experiments of longer duration of hypoglycemia that cause 3-6 fold more brain
damage than observed in the current study indeed do result in demonstrable deficits in
Morris maze testing60. Although considered, the relatively high mortality in the current
series of rats precluded hypoglycemia experiments of longer duration. Interestingly, a
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dissociation between severe hypoglycemia-induced brain damage and detectable
cognitive deficit is consistent with clinical studies in which severe hypoglycemia alters
brain structure4 yet detectable cognitive deficits are seen in some4,8 but not all59 studies.
Consistent with a previous report from our lab revealing that diabetic rats are
more susceptible to severe hypoglycemia-induced death141, mortality due to severe
hypoglycemia tended to be increased in both the uncontrolled diabetic (STZ) and
insulin-treated diabetic (STZ+Ins) rats compared to controls. However, since the
difference was not significant, future research is focusing on how diabetes per se might
increase risk of severe hypoglycemia-induced death. While the cause of death in the
current experiments is unknown, it is hypothesized that severe hypoglycemia induces
fatal cardiac arrhythmias which is further discussed in chapter 4.
Hypoglycemia has been shown to induce neuronal cell death via a cascade of
molecular events, including increased release of glutamate, calcium, zinc, and reactive
oxygen species, leading to cell death142. The mechanism by which hypoglycemiainduced neuronal damage was markedly augmented in diabetic rats was not directly
assessed in these studies although many potential mechanisms exist. 1) The greater
net drop in glycemia experienced in the diabetic rats (i.e. from 484 to 13 mg/dl) may
have exacerbated brain damage. 2) The decreased number of brain glucose
transporters103 and altered glucose transport and metabolism 143 may have led to the
increased susceptibility to brain damage in the diabetic rats. 3) An up-regulation of
glutamate leading to calcium overload may have enhanced neuronal death in diabetic
rats144. 4) STZ-diabetic rats show a down regulation of cortical NMDA receptors145,
which may be particularly important given the role of excess glutamate in mediating
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hypoglycemia-induced neuronal damage146. 5) Following the hypoglycemic episode, the
effects of chronic hyperglycemia may have been toxic to vulnerable neurons resulting in
increased brain damage147.
In the absence of severe hypoglycemia, uncontrolled diabetes (induced by
streptozotocin) does not result in brain damage as shown by a previous report 61.
Therefore, in the current studies, diabetic rats not subjected to severe hypoglycemia
(STZ-NH) were not analyzed for brain damage.
The mechanism by which chronic insulin therapy afforded neuroprotection
against brain damage cannot be precisely determined in this model. It was
hypothesized that chronic insulin deficiency may predispose the diabetic brain to greater
hypoglycemia-induced damage. Studies in ischemic brain injury models are consistent
with the notion that insulin directly acts in the brain to afford neuroprotection 64,67.
Alternatively, since the down regulation of brain glucose transporters by chronic
hyperglycemia103 may predispose the brain to profound neuroglycopenia in response to
acute severe hypoglycemia, it may be that the correction of chronic hyperglycemia
alone could be neuroprotective. Another possible mechanism for the neuroprotective
effect of chronic insulin therapy could be related to the preconditioning effect of
recurrent hypoglycemia60. Although rats that displayed recurrent hypoglycemia were
specifically excluded from the study, we cannot rule out the possibility that in an attempt
to achieve near normalization of blood glucose levels, some of the insulin treated
diabetic rats might have had episodes of undetected antecedent hypoglycemia which
could have preconditioned the brain and protected it against the subsequent severe
hypoglycemic episode60. Regardless of the mechanism, the effect was profound. The
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10-15 fold reduction in hypoglycemia-induced brain damage indicates that antecedent
blood glucose achieved with chronic insulin therapy is a major beneficial therapeutic
intervention that provided the diabetic rats significant neuroprotection.
For patients and clinicians, the choice to pursue an intensive insulin regime as a
therapeutic approach to realize the established long-term microvascular benefits
associated with tight glycemic control, has to be weighed against the increased risk of
severe hypoglycemia and associated adverse outcomes including brain damage. In this
study, chronic insulin treatment in diabetic rats that lead to a near normalization of
glucose levels, markedly reduced the extent of brain damage induced by severe
hypoglycemia. These intriguing findings indicate that chronic insulin therapy that
improved glycemic control, paradoxically, rendered the diabetic rats more prone to, but
less vulnerable to, an episode of severe hypoglycemia. In conclusion, antecedent blood
glucose control represents a major modifiable therapeutic intervention that can afford
diabetic

subjects

neuroprotection

against

hypoglycemia-induced brain damage.
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Chapter 4. Sudden Deaths due to Lethal Cardiac Arrhythmias during Severe
Hypoglycemia are Mediated by Sympathoadrenal Activation
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Abstract
For people with insulin treated diabetes, severe hypoglycemia can be lethal.
Potential mechanisms by which hypoglycemia can lead to sudden death are not well
understood. To study how severe hypoglycemia can be fatal, 1-3 hour hyperinsulinemic,
severe hypoglycemic (10-15 mg/dl) clamps were performed in Sprague-Dawley rats
with simultaneous continuous electrocardiogram recording. With a goal towards
reducing severe hypoglycemia induced mortality, the hypotheses tested were: 1)
antecedent glycemic control impacts ability to survive an episode of severe
hypoglycemia, 2) by limiting hypokalemia, potassium supplementation could limit
cardiac arrhythmic deaths, 3) by preventing central neuroglycopenia, brain glucose
infusion could prevent hypoglycemia associated arrhythmic deaths, and 4) by limiting
the effects of sympathoadrenal activation during hypoglycemia, adrenergic blockers
could provide a survival advantage by preventing lethal cardiac arrhythmias. Mortality
rates associated with severe hypoglycemia were worsened by diabetes, but recurrent
antecedent hypoglycemia markedly improved survival. Potassium supplementation
trended to reduce mortality in non-diabetic and diabetic rats. Severe hypoglycemia
caused numerous cardiac arrhythmias including premature ventricular contractions, 1st,
2nd, and 3rd degree heart block, and ventricular tachycardia. Intracerebroventricular
glucose

infusion

reduced

cardiac

arrhythmias

and

mortality

due

to

severe

hypoglycemia. Beta adrenergic blockade reduced cardiac arrhythmias and completely
abrogated deaths due to severe hypoglycemia. In conclusion, severe hypoglycemia
induced sudden death was preceded by fatal cardiac arrhythmias. Mortality was entirely
prevented by blocking the effective sympathoadrenal response. It is concluded that
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brain

neuroglycopenia

and

the

marked

catecholaminergic

sympathoadrenal

counterregulatory response are the primary mediators of fatal cardiac arrhythmias
induced by severe hypoglycemia.
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Introduction
The rate of sudden death in young people with Type 1 diabetes is 10-fold higher
than age matched controls78. Sudden nocturnal deaths account for up to 27% of all
unexplained deaths in people with Type 1 diabetes 75,77. The aptly named “dead in bed
syndrome” identifies otherwise healthy young individuals with Type 1 diabetes that were
found dead in bed with no clear cause of death 69-71,73-78. It has been speculated that
their deaths were due to excess insulin administration and resultant severe
hypoglycemia70-74,76,77,80. However, the mechanisms by which severe hypoglycemia can
be lethal is unclear.
The brain requires a constant supply of glucose to function normally. During
hypoglycemia, lack of glucose supply to neurons can lead to confusion, brain damage 81,
seizures82,83 and if hypoglycemia is low enough for long enough, it may be fatal. Indeed,
6-10% of deaths in people with Type 1 diabetes are directly attributable to
hypoglycemia59,148,149. It has been hypothesized that acute onset cardiac arrhythmias
contribute to severe hypoglycemia-induced sudden death. Clinical studies using
electrocardiograms (ECG) have found that cardiac arrhythmias associated with QTc
prolongation occur during moderate hypoglycemia85-89. Prolongation of the QTc interval
can lead to increased risk of fatal cardiac arrhythmias 91-93. It remains undetermined to
what extent severe hypoglycemia induced cardiac arrhythmias are mediated by central
neuroglycopenia versus systemic factors affecting cardiac tissue.
In the setting of insulin-induced hypoglycemia, both the insulin-induced
decrement in potassium levels and the counterregulatory-induced increase in
catecholamine levels have been speculated to contribute to arrhythmias88,97,98. It has
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been shown previously that potassium or beta blockers can reduce cardiac arrhythmias
in patients during moderate hypoglycemia (~45 mg/dl)88. It is well established that
increased catecholamine levels can lead to ventricular arrhythmias95,96. However, it
remains to be determined whether the prevention of hypokalemia and/or blocking the
actions of the catecholamines protect against lethal arrhythmias and cardiorespiratory
arrest during the setting of severe hypoglycemia.
In order to determine preventable causes of death during severe hypoglycemia,
protocols described below describe how experimental rats were monitored for cardiac
arrhythmias and mortality during an episode of severe hypoglycemia during which time
putative protective agents were administered.

Methods
Animals. Nine-week-old male Sprague-Dawley rats (Charles River Laboratories) were
housed individually in a temperature- and light-controlled environment fed ad libitum
with standard rat chow diet and water. All studies were done in accordance with and
approved by the Animal Studies Committee at Washington University School of
Medicine.

Implantation of arterial and venous catheters and ECG leads. Nine week old male,
Sprague Dawley rats were anesthetized with an intraperitoneal injection of Ketamine 87
mg/kg and Xylazine 2.6 mg/kg. A micro-renathane® (Braintree Scientific, Boston, MA)
catheter was inserted into the left carotid artery for sampling access and two catheters
were implanted into the right jugular vein for infusions. To maintain patency, at the time
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of implantation catheters were filled with a 40% polyvinylpyrrolidone (Sigma) in heparin
(1000 USP U/ml) solution (Baxter Healthcare Corporation, Deerfield, IL). In some
studies, at the time of surgery one electrocardiogram (ECG) wire lead was placed in the
right supraclavicular fossa and another wire lead was placed exterior to the lower left rib
cage, in the mid axillary line, to approximate clinical lead II position. ECG wire leads
were secured and sutured in place to the underlying muscle. A reference lead was
placed subcutaneously over the back. The free ends of the three wire leads and vessel
catheters were buried subcutaneously on the animal’s back for easy retrieval on the day
of the clamp. Rats were allowed to recover for 4-10 days. All rats had restored their preoperative weight before being subjected to the hypoglycemic clamp.

Hyperinsulinemic-severe hypoglycemia clamp. After an overnight fast, vascular
catheters and ECG leads were externalized under brief isoflorane anesthesia. Animals
were allowed to rest for 1.5 to 2 hours before basal samples were taken. Awake,
unrestrained rats were subjected to hyperinsulinemic (0.2 U · kg−1 · min−1) severe
hypoglycemic (10-15mg/dl) clamps for 3 hours unless otherwise noted. Rats had free
access to water. Insulin (Humulin R; Eli Lilly, Indianapolis, IN) and glucose (50%
dextrose; Hospira, Lake Forest, IL) were co-infused intravenously to lower blood
glucose to 10-15 mg/dl over a period of 2 to 2 ½ hours. During the first hour of insulin
infusion, glucose levels were maintained at ~70 mg/dl in order to assess the effects of
hyperinsulinemia on the electrocardiogram, in the absence of profound hypoglycemia.
Arterial blood samples were obtained every 15 minutes to measure blood glucose
(Ascensia Contour blood glucose monitors, Bayer HealthCare, LLC, Mishawaka, IN). All
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experimental groups were precisely matched for duration and depth (10-15 mg/dl) of
hypoglycemia. Mortality due to severe hypoglycemia was determined by cessation of
breathing.
Blood samples were taken during the basal period and at various times
throughout the severe hypoglycemic clamp for epinephrine, norepinephrine, glucagon,
and insulin measurements. Insulin was measured by ELISA (Crystal Chem, Downers
Grove, Il). Glucagon was measured by RIA (Millipore, Billerica, MA). Plasma
epinephrine and norepinephrine levels were determined by a single isotope derivative
(radioenzymatic) method112. Blood pressure (Noninvasive BP monitor, Columbus
instruments, Columbus, OH) was measured by tail cuff in the basal period and every 15
minutes during severe hypoglycemia in select studies.

Arterial blood gas and electrolytes. Blood samples were taken at various timepoints
throughout the clamp for analysis of potassium, oxygen, carbon dioxide, calcium, and
pH on an ABG machine (pHOx Plus C, Nova Biomedical, Waltham, MA). Respiration
was calculated as breaths per minute by visibly counting breaths.

Seizures. Episodes of seizure-like behavior were noted during the severe hypoglycemic
clamps. Tonic-clonic seizure-like behavior was visually noted by characteristic brief (510 seconds) neck extensions, tonic stretching, uncontrolled limb movements, and
spontaneous spinning61,150. The incidence of seizure-like behavior was quantified for
each rat during the clamp period. A subset of rats also had electroencephalogram
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(EEG) recording (XLTEK Video EEG System, Oakville, Ontario) to analyze brain waves
before, during, and after hypoglycemia-induced seizures.
Study 1: Overall mortality analysis in control, diabetic and recurrently
hypoglycemic experiments. Control (n=123), diabetic (n=95), and recurrent
hypoglycemic (n=27) rats that underwent 1 hour of severe hypoglycemia 60,61,146 were
analyzed for mortality.
Diabetes. Approximately two weeks before the severe hypoglycemic clamp, diabetes
was induced by intraperitoneal injection of streptozotocin (STZ; 65 mg/kg; Sigma) as
previously described61. Control non-diabetic rats received vehicle injections of 0.1 mM
sodium citrate (Fisher Scientific) buffer. Some rats were injected with a second dose of
STZ to ensure random glucose >300 mg/dl (Ascensia Contour BG monitors, Bayer
HealthCare, Mishawaka, IN).
Recurrent hypoglycemia. For three consecutive days before the severe hypoglycemic
clamp, moderate hypoglycemia (25-40 mg/dl) was recurrently induced in non-diabetic
rats with injections of subcutaneous regular human insulin (Lilly, Indianapolis, IN; 6 U/kg
on day 1; 5 U/kg on day 2; and 4 U/kg on day 3) as previously described60. Control rats
received saline injections. Severe hypoglycemic clamps were performed on the 4 th day.

Study 2: Potassium supplementation. Potassium (KCl, 0.375 mEq/ml, Hospira, Lake
Forest, Il) was infused with saline at 4 μl/min. Non-diabetic rats either received (n=12) or
didn’t receive (n=15) potassium and diabetic rats either received (n=28) or didn’t receive
potassium (n=45) throughout a hyperinsulinemic/severe hypoglycemic clamp, as
described above.

89

Study 3: Cardiac arrhythmias in control experiments
ECG studies. To explore the possibility of arrhythmias as a possible cause of death,
control non-diabetic rats (n=6) underwent severe hypoglycemic clamps for 90 minutes
as described above, with continuous ECG recording (ADI Powerlab 26T, Colorado
Springs, CO). ECG analyses included heart rate, QTc length, and other arrhythmias
(ADI LabChart Pro 7). QTc was calculated using Bazett’s formula 151. Cardiac
arrhythmias were analyzed for incidence and frequency. For frequency analysis,
arrhythmias were counted individually and divided by the amount of time spent in
severe hypoglycemia (either 180 or minutes or time of death).

Study 4: ICV glucose infusion. Using a digital stereotactic neurosurgery apparatus
and under continuous 1% isofluorane anesthesia, intracerebroventricular (ICV)
cannulas (internal cannula 31g, outer guide cannula 24g, 9.5mm depth; Plastics One
Inc, Roanoke, VA) were placed on the skull in the midline -2.8 mm posterior to bregma.
Screws were affixed to the bare skull and glue was applied (SNAP, Parkell Inc,
Edgewood, NY) to fasten the cannula in place. Rats were allowed to recover 1 week
post ICV surgery before implantation of vascular catheters and ECG leads as described
above. On the day of the clamp, the ICV cap was removed and a cannula primed with
either 2mM D-glucose (n=9) (Sigma, St. Louis, MO) or 2mM D-mannitol (n=9) (Sigma)
was placed in through the guide cannula. Glucose or mannitol (as a control) were
infused at 0.1 l/min via the internal ICV cannula at the start, and throughout, the
hyperinsulinemic/severe hypoglycemic clamp, as described above. Correct ICV cannula
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placement in the third ventricle was confirmed in all rats studied by post mortem staining
with Evan’s blue dye.

Study 5: Adrenergic blockade. On the day of the clamp, after a 2 hour basal period, 
(prazosin, Sigma, 1 receptor blocker, 1 mg/ml dissolved in sterile distilled water and
infused at 1 l/min) and  (propranolol, Sigma, 1/2 receptor blocker, 1 mg/ml infused
at 2.5 l/min) blockers were infused intravenously either concurrently (n=13) or
individually (n=5-6) starting 30 minutes prior to insulin infusion and continued throughout
the severe hypoglycemic clamp, as described above. Saline was infused in controls
(n=12). The drug doses chosen were based on previous studies describing the use of
adrenergic blockers in rats98 and by pilot studies.

Statistical analyses. All data are represented as mean+sem. Analysis of variance
(one- and two-way where appropriate), repeated measures ANOVA, and student’s t-test
were used to determine significance. Holm-Sidak’s and Dunn’s method were used for
post-hoc analyses. Fisher exact test with the Freeman-Halton extension was used to
determine significance for mortality and arrhythmia incidence. Significance was
determined by p<0.05.

91

Results
Study 1: Overall mortality analysis in control, diabetic and recurrently
hypoglycemic experiments
In order to understand how diabetes and recurrent hypoglycemia might affect the
ability to survive an episode of severe hypoglycemia, rats were placed into 3 groups: 1)
control, non-diabetic, 2) uncontrolled diabetic (streptozotocin), and 3) recurrent
moderate hypoglycemia (3 days of glucose 25-40 mg/dl for 3 hours). Basal morning
glucose levels for control non-diabetic rats were 88±5 mg/dl. Uncontrolled STZ-diabetic
rats had a fasted basal glucose of 348±37 mg/dl. Rats that underwent recurrent
hypoglycemia had a basal glucose of 74±2 mg/dl. All three groups of rats underwent a
hyperinsulinemic/severe hypoglycemic clamp for 1 hour. During severe hypoglycemia,
mean

glucose

levels

were

similar

for

control

(11.5±0.21mg/dl),

diabetic

(12.1±0.24mg/dl), and recurrent hypoglycemia (11.9±0.41mg/dl) rats. The epinephrine
response to hypoglycemia was normal in diabetic rats, but epinephrine was blunted in
recurrent hypoglycemia rats (2001±241 vs 3487±474 pg/ml in controls 60). All rats lost
their righting reflex, went into a coma, and experienced brief seizure like activity.
Analysis of severe hypoglycemia induced mortality rates was found to be 21% in
control, non-diabetic rats and increased to 36% in diabetic rats (p<0.05; Figure 20A).
Interestingly, rats that had been previously treated with the recurrent moderate
hypoglycemia protocol had markedly less mortality (only 4%) during their severe
hypoglycemic clamp (p<0.05; Figure 20A). Differences in death rates were
hypothesized to be due to hypokalemia, neuroglycopenia, and/or the sympathoadrenal
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response, each of which could have increased susceptibility to cardiac arrhythmias and
are each individually tested in the subsequent experiments.

Study 2: Potassium supplementation
In order to determine if cause of death due to severe hypoglycemia resulted from
hypokalemia, potassium was supplemented in non-diabetic and diabetic rats during a 1
hour severe hypoglycemic clamp. Morning basal glucose levels were similar for rats that
either received or did not receive potassium supplementation. Control rats had basal
glucose levels of 127±7 mg/dl and 116±12 mg/dl, respectively. Basal glucose levels for
diabetic rats were 479±77 mg/dl and 394±54 mg/dl, respectively. Mean glucose levels
during severe hypoglycemia were not different among the non-diabetic rats that did
(12.6±1.18mg/dl) or did not (12.5±0.76mg/dl) receive potassium or the diabetic rats that
did (12.1±0.84mg/dl) or did not (13.4±0.39 mg/dl) receive potassium. Potassium levels
decreased during severe hypoglycemia in both non-diabetic rats (from 4.2+0.15 to
2.9+0.06 mmol/l) and in diabetic rats (from 4.0+0.11 to 2.9+0.23 mmol/l) that did not
receive potassium (Figure 20B). With potassium supplementation, potassium levels
were maintained during severe hypoglycemia compared to basal in non-diabetic
(4.4+0.26 to 3.9+0.38mmol/l) and diabetic (4.5+0.25 to 3.8+0.47mmol/l) rats (Figure
20B). Mortality associated with severe hypoglycemia trended to be reduced with
potassium supplementation compared to rats that did not receive potassium
supplementation in both non-diabetic (from 33% to 8%) and diabetic (from 44% to 25%)
rats, but this did not reach significance (p<0.08; Figure 20C).
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Study 3: Cardiac arrhythmias in control experiments
We observed that sudden death in the setting of severe hypoglycemia seemed to
be related to electrolyte (i.e. potassium) concentration. Since hypokalemia can be proarrhythmic, in order to determine if severe hypoglycemia induced mortality is mediated
by

cardiac

arrhythmias,

control,

non-diabetic

rats

(n=6)

were

subjected

to

hyperinsulinemic/severe hypoglycemic clamps with continuous ECG recording. Glucose
levels were gradually decreased and glucose was held between 10-15 mg/dl for 90
minutes (Figure 21A). With this longer duration of severe hypoglycemia, all the rats died
(Figure 21B).
Following insulin administration and during the initial period of moderate
hypoglycemia, heart beats per minute (bpm) remained normal as compared to the basal
state (Figure 21C). It was not until severe hypoglycemia that heart rate increased.
Additionally, during severe hypoglycemia, multiple cardiac arrhythmias were noted,
discussed below. Heart rate was variable toward the end of severe hypoglycemic due to
the few survivors towards the end of the clamp and due to the multiple types of cardiac
arrhythmias that tended to, in some cases, reduce the heart rate while at other times
increase the heart rate. Periods of tachycardia (>400 bpm) as well as bradycardia (<300
bpm) were noted with increasing frequency with the duration of severe hypoglycemia.
Widening of the QTc complex as noted on the ECG rhythm, represents
dispersion of ventricle depolarization and repolarization and is known to be proarrhythmic. Marked QTc prolongation was observed shortly after insulin infusion when
glucose levels were only in the moderate hypoglycemia range (47+6 mg/dl) (Figure
21D). As compared to basal QTc of 122+2ms, peak QTc during severe hypoglycemia
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was 172+8ms, indicating a 40% increased ventricular depolarization and repolarization
phase (p<0.001).
Epinephrine

and

norepinephrine

increased

during

severe

hypoglycemia

compared to the basal period (p < 0.001; Figure 21E,F; Table 1). Plasma epinephrine
peaks around the start of severe hypoglycemia and decreases as severe hypoglycemia
prolongs indicating possible adrenal failure. Plasma norepinephrine gradually increases
during severe hypoglycemia.
In the setting of hypoglycemia, QTc prolongation, hypokalemia, and elevated
catecholamines can increase risk of cardiac arrhythmias. Cardiac arrhythmias did not
occur during early moderate hypoglycemia. It was only following 15 minutes of severe
hypoglycemia did premature ventricular contractions (PVCs) and narrow complex
second degree heart block (Mobitz II) started to be noted as the initial cardiac
arrhythmias (Figure 22). Frequency of PVCs and 2nd degree heart block were 1.4+0.7
and 2.1+0.8 per minute, respectively (Figure 23A). In addition, other cardiac arrhythmias
typically seen during severe hypoglycemia were premature atrial contractions (PACs)
and 1st degree heart block (Figure 22). Occasionally, brief (<10 seconds) runs of
ventricular fibrillation and non-sustained ventricular tachycardia were noted, but these
rhythms were not noted to precede sudden death (Figure 23B). During severe
hypoglycemia, a consistent pattern of sequential progression of arrhythmias that
preceded cardiorespiratory arrest was carefully noted. With prolonged hypoglycemia,
more frequent and longer duration second degree heart block as well as higher grade
second degree heart block (ie, atrial:ventricular conduction ratio of 4:1) were noted.
Following second degree heart block, the most commonly noted terminal arrhythmias
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were third degree heart block (complete atrioventricular dissociation), characterized by
a terminal bradycardic ventricular rhythm (Figure 22).
Arterial blood gas and electrolytes. Oxygen and carbon dioxide levels remained normal
throughout the experiment until just prior to death, where oxygen levels decreased and
carbon dioxide levels increased (Figure 23C, Table 1).
Potassium levels decreased during severe hypoglycemia compared to the basal
period (p< 0.05, Table 1). In the moribund phase, potassium levels increased. Following
a similar pattern, pH levels also remained normal throughout the clamp and only
decreased just prior to death (p<0.05, Table 1). Calcium and bicarbonate levels did not
change during severe hypoglycemia (Table 1).
Blood pressure. Blood pressure increased from 105+14/60+2 during the basal period to
177+16/93+9 mmHg during severe hypoglycemia (Figure 23D). Blood pressure
remained elevated until immediately prior to death when it suddenly decreased. Before
becoming immeasurable, the last recorded blood pressure was 77+10/59+10 mmHg.
Seizures.

Seizure-like

activity

was

noted

in

all

rats

that

underwent

hyperinsulinemic/severe hypoglycemic clamps. Seizure-like activity was quantified by
counting the number of characteristic, brief (<5 sec), myoclonic convulsions. A subset of
rats also had simultaneous EEG recording during the clamp. During severe
hypoglycemia, EEG tracings showed characteristic high-amplitude slow waves and
EEG isoelectricity coincided with a non-responsive comatose state (Figure 24). Also
during severe hypoglycemia, high frequency high amplitude spikes of increased
electrical activity were noted during seizures. Given that all severely hypoglycemic rats
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had seizures, yet only a fraction of severe hypoglycemic rats died, it was not surprising
that no correlation was found between seizure activity and mortality.

Study 4: ICV glucose infusion
In order to understand and to isolate the extent to which neuroglycopenia during
hypoglycemia mediates sudden death, glucose was infused into the 3 rd ventricle of the
brain during the severe hypoglycemic clamps to prevent brain neuroglycopenia.
Compared to controls, ICV glucose infusion reduced mortality due to severe
hypoglycemia from 86% to 33% (p < 0.05; Figure 25A). Systemic blood glucose was
similar during severe hypoglycemia in ICV mannitol (MAN, n=9) and ICV glucose (GLU,
n=9) infused rats (11.7+0.1 vs 12.2+0.2 mg/dl, respectively; p = 0.13; Figure 25B; Table
2). Despite matched glucose levels, ICV glucose infused rats required a higher
peripheral glucose infusion rate (5.4+0.56 mg/kg/min; p < 0.005) during severe
hypoglycemia compared to MAN (4.1+0.41 mg/kg/min; Figure 25C). Insulin levels were
comparable between both groups during basal and severe hypoglycemia (Table 2).
ECG analyses. During severe hypoglycemia, heart rate was significantly lower in the
GLU group compared to the MAN group (p<0.05, Figure 25D). Mean heart rate
increased in the ICV mannitol group from 373+4 in the basal to 414+9 BPM during
severe hypoglycemia (p < 0.01) while ICV glucose infusion prevented this rise in heart
rate (basal:357+4 vs. severe hypoglycemia:357+8 BPM). Mortality incidence was
associated with duration of sinus tachycardia (heart rates greater than 400 BPM; Figure
26A); however, ICV glucose infused rats had decreased mortality compared to ICV
mannitol infused rats despite more than 30 minutes of tachycardia.
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QTc increased during severe hypoglycemia compared to basal in both MAN and
GLU groups with no significant differences between the groups (p = 0.14; Figure 25E).
Greater QTc length was associated with an increased mortality risk (Figure 26B).
However, mortality rate was lower in ICV glucose infused rats compared to ICV
mannitol infused rats despite QTc prolongation.
Cardiac arrhythmias were absent in 25% of the ICV glucose infused rats.
Frequencies of PVCs and second degree heart block were nonsignificantly reduced with
ICV glucose infusion compared to ICV mannitol infusion (p<0.07 and p<0.06,
respectively; Figure 26C,D). Incidence of 3rd degree heart block was decreased in the
GLU group compared to the MAN group (p<0.05; Figure 26E). Third degree heart block
was observed just before death in all rats that died in both groups. Rats that lived did
not experience third degree heart block suggesting that third degree heart block was the
terminal fatal arrhythmia associated with severe hypoglycemia. Other life threatening
arrhythmias such as ventricular tachycardia leading to ventricular fibrillation was
witnessed in 33% of the MAN group and 0% of the GLU group but this difference was
not significant (Figure 26F).
Epinephrine increased in both the MAN and GLU groups during severe
hypoglycemia to 1926+320 and 2155+448 pg/ml, respectively, with no difference
between the groups (Table 2). Norepinephrine increased in the MAN group during
severe hypoglycemia (1441+646 pg/ml) but this response was attenuated in the GLU
group (464+48 pg/ml) (p< 0.05; Figure 25F, Table 2). Interestingly, just prior to death,
norepinephrine was significantly elevated in ICV glucose infused rats (p<0.001 vs
severe hypoglycemia; Table 2).
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Arterial blood gas and electrolytes. Potassium levels significantly decreased during
severe hypoglycemia in both the MAN and GLU groups compared to basal (Table 2).
Potassium during severe hypoglycemia was significantly lower in the GLU group
(p<0.05).
Oxygen and carbon dioxide levels did not change during severe hypoglycemia
(Table 2). Just before respiratory arrest in MAN and GLU rats that died, oxygen
decreased to 35+10 and 18+17%, respectively, and carbon dioxide increased to 47+3
and 53+5 mmHg, respectively (Table 2).
Mean respiration during severe hypoglycemia for the MAN and GLU groups was
not different (85+4.4 and 78+4 breaths per minute, respectively; Table 2) but ICV
glucose infused rats had lower respiration during severe hypoglycemia compared to
basal. Respiration decreased just prior to death in the MAN and GLU groups,
respectively (p <0.01 vs basal; Table 2).
Seizure occurrence was 100% in the MAN group but only 78% in the GLU group;
however, this was not statistically significantly different (data not shown).

Study 5: Adrenergic blockade
In order to test the hypothesis that the sympathoadrenal response increases risk
of fatal cardiac arrhythmias during severe hypoglycemia, rats had adrenergic receptors
blockers infused during a 3 hour hyperinsulinemic/severe hypoglycemic clamp. Mortality
associated with severe hypoglycemia was 33% in control rats (n=12) while both
combined  and  blocker infusion (, n=13) and  blocker infusion alone (n=5)
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completely prevented death (p < 0.029; Figure 27A).  blocker infusion alone had no
effect on mortality (50%; n=6).
Glucose levels during severe hypoglycemia were equally matched in control,
combined / blocker,  blocker alone, and  blocker alone infused rats (11.7+0.2,
12.3+0.3, 11.6+0.5, and 12.4+0.5 mg/dl, respectively; Figure 27B). Consistent with a
blunted effective counterregulatory response, glucose infusion rate was increased
during severe hypoglycemia in / blocker infused rats (4.87+0.24mg/kg/min; p < 0.01;
Figure 27C) compared to controls (3.3+0.41mg/kg/min). Glucose infusion rates during
severe hypoglycemia were nonsignificantly increased in  blocker infused rats (4.5+0.65
mg/kg/min) and nonsignificantly decreased in  blocker infused rats (2.1+0.61
mg/kg/min) compared to controls (p = 0.12; Figure 27C). Insulin levels were not
significantly different between the groups (Figure 28A).
ECG analyses. Heart rate was variable throughout the clamp. During severe
hypoglycemia mean heart rate was 331+5, 225+5, 339+9, and 198+4 BPM in CON, /
blocker,  blocker, and  blocker infused rats, respectively (Figure 27D). /and 
blocker infused rats had significantly lower heart rates during severe hypoglycemia
(p<0.05, ANOVA). While soon after the start of insulin infusion and glucose lowering the
 blocker infused rats had a higher heart rate compared to controls, during severe
hypoglycemia heart rate was similar to controls. The lower heart rate in the / blocker
and  blocker infused rats indicates that the effects of beta blockade were working to
prevent the rise in heart rate seen in control rats. Additionally, increased heart rate in 
blocker infused rats indicates that the alpha blockade treatment was effective. In the
control and  blocker groups, sinus tachycardia (heart rate greater than 400 BPM) was
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experienced in all of the rats that died with more than 30 minutes of tachycardia
resulting in 100% mortality (Figure 28B). Treatment with  blocker, and combined /
blocker completely abrogated the hypoglycemia induced tachycardia and mortality.
Therefore, sinus tachycardia is a predictor of mortality in these experiments and
prevention of tachycardia was associated with a mortality benefit.
From baseline levels, there was significant QTc prolongation during severe
hypoglycemia in control (105+6 to 163+2ms),  blocker (129+3 to 210+5ms), and 
blocker (117+3 to 164+2 ms) infused rats (p < 0.001) but QTc prolongation was blunted
in / blocker (99+2 to 134+3ms; p < 0.001) infused rats compared to controls (Figure
27E). QTc prolongation was associated with an increased risk of mortality in the control
and  blocker rats (Figure 28C). In control and  blockade rats, markedly increased
QTc prolongation lengths of more than 200ms resulted in 33% and 67% mortality,
respectively. Interestingly, the  blocker infused rats had increased QTc prolongation
very similar to control rats (Figure 27E) yet had a 100% survival rate indicating that QTc
prolongation alone may not be a direct mediator of lethality associated with severe
hypoglycemia, but rather may be a harbinger of impending mortality. QTc prolongation
appears to be a marker of severe hypoglycemia, but is not in itself sufficient to trigger
the more lethal types of cardiac rhythms.
While the control and  blocker infused rats experienced PACs, PVCs, and 1st,
2nd, and 3rd degree heart block, the / blocker and  blocker infused rats mostly only
experienced a few PACs, PVCs and 2nd degree heart block but with less frequency.
PVCs occurred in 25% of the rats with / blocker infusion but only during or after a
visible seizure whereas heart block occurred in only 8% of the rats (p<0.001). Single
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and  blocker infused rats had reduced arrhythmias overall compared to controls.
Frequency of PVCs was reduced in combined / blocker and  blocker infused rats
compared to controls (p<0.001; Figure 29A). Although  blocker infused rats trended to
have lower frequency of PVCs, there was no significant difference compared to
controls. Frequency of 2nd degree heart block was significantly reduced in combined /
blocker (0.0004+0.0004 per minute; p< 0.001) and trended to be reduced in  blocker
(0.08+0.06 per minute), and  blocker (0.17+0.18 per minute) infused rats compared to
controls (1.1+0.43 per minute; Figure 29B). Third degree heart block was prevented in
/ blocker and  blocker infused rats but was only significantly different with /
blocker infusion (p< 0.024; Figure 29C). Rats with  blocker infusion experienced
similar incidence of 3rd degree heart block as controls. These results indicate that
although  blocker infusion is sufficient to prevent death, both  and  adrenoreceptors
need to be blocked to nearly completely prevent arrhythmias.
Epinephrine

and

norepinephrine

significantly

increased

during

severe

hypoglycemia compared to basal in control, / blocker,  blocker, and  blocker
infused rats (Figure 29D,E); however, while measurable in the peripheral circulation, the
actions of epinephrine and norepinephrine were dually blocked with combined /
blockade or partially blocked with single  or blockade. Epinephrine peaked during the
first 30 minutes of severe hypoglycemia and was significantly higher in  blocker infused
rats (5610+599pg/ml) compared to controls (2603+353pg/ml; p<0.004) and / blocker
infused rats (3097+396; p<0.011; Figure 29D). Epinephrine levels in  blocker infused
rats (3335+716 pg/ml) were not different from controls. Norepinephrine was significantly
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increased in the  blocker group (2720+435pg/ml; p<0.001) compared to the control
(667+164 pg/ml), / blocker (591+69 pg/ml), and  blocker groups (1006+312 pg/ml;
Figure 29E).
Glucagon increased during severe hypoglycemia compared to basal in control,
/ blocker, and  blocker infused rats with no significant difference in  blocker infused
rats. Glucagon was significantly higher in  blocker infused rats compared to all three
groups (p<0.001 for AUC; Table 3). Elevated glucagon is consistent with the elevated
norepinephrine in the  blocker group which may be acting on beta adrenergic
receptors on pancreatic alpha cells to stimulate glucagon secretion at a higher rate
compared to controls.
Arterial blood gas and electrolytes. Mean potassium levels decreased in all groups
during severe hypoglycemia although potassium was significantly higher in  blocker
infused rats (p <0.01, Table 3). The similar degree of low potassium between the
control, / blocker, and  blocker infused rats indicates that in the setting of severe
hypoglycemia, hypokalemia alone is not sufficient to cause cardiac arrhythmias
because / blocker infusion prevents arrhythmias in the presence of hypokalemia.
Oxygen saturation and carbon dioxide levels were normal for all groups
throughout the clamp (Table 3). Control rats had a mean respiration during severe
hypoglycemia of 76+3 breaths/min (Table 3). Respiration decreased in the / blocker
and  blocker infused rats to 51+2 and 54+2 breaths/min, respectively (p < 0.001), while
 blocker infused rats had similar respiration (65+8 breaths/min) compared to controls.
Decreased respiration was consistent with higher carbon dioxide levels in / blocker
and  blocker infused rats versus controls (p < 0.001; Table 3). Respiration decreased
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in the control and  blocker infused rats just prior to death with a concomitant decrease
in oxygen and increase in carbon dioxide levels (Table 3).
Seizure like activity was witnessed in 100% of the control,  blocker, and 
blocker infused rats but only 71% of the / blocker infused rats (data not shown).
However, this difference was not significant and no correlations were found between
seizure-like activity and mortality.
Blood pressure. Mean systolic blood pressure during severe hypoglycemia for control,
/ blocker,  blocker, and  blocker infused rats was 133+14, 140+10, 129+8, and
112+4 mmHg with  blocker infusion resulting in a significantly lower blood pressure
(p<0.001; Figure 28D). Mean diastolic blood pressure during severe hypoglycemia was
91+16, 90+9, 92+8, and 77+4 mmHg, respectively, with a significantly lower blood
pressure in  blocker infused rats (p<0.001; Figure 28E). Most importantly blood
pressure did not suddenly increase or decrease prior to death in any of the groups
indicating that blood pressure is maintained throughout severe hypoglycemia.
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Figure 20. Severe hypoglycemia induced mortality in diabetic, non-diabetic,
recurrently hypoglycemic rats, and the effects of potassium supplementation
(studies 1 and 2). A) Analysis of morality associated with severe hypoglycemia
revealed 21% mortality in non-diabetic control rats (n=123). Mortality was increased in
diabetic rats to 36% (n=95) and decreased to 4% (n=27) in rats that underwent
recurrent hypoglycemia prior to severe hypoglycemia (*p<0.05 Fisher exact test,
Freeman-Halton extension). B) Potassium levels in rats that had no potassium
supplementation (No K+, non-diabetic: white bar, diabetic: diagonal slash) versus rats
with potassium supplementation (K+, non-diabetic: black bar, diabetic: horizontal slash)
both in the basal state and during severe hypoglycemia. Rats without supplementation
had potassium levels significantly decrease during severe hypoglycemia while rats with
supplementation maintained normal potassium during severe hypoglycemia. Potassium
levels in nondiabetic rats without potassium (white bar), nondiabetic rats with potassium
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(diagonal slash), diabetic rats without potassium (black bar), diabetic rats with
potassium (horizontal slash). C) Potassium supplementation in nondiabetic and diabetic
rats trended to reduce severe hypoglycemia-induced mortality from 33 to 8% (n=12-15)
and 44 to 25% (n=28-45), respectively, but this did not reach significance. Data
expressed as mean+sem.
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Figure 21. Severe hypoglycemic clamp in control experiments (study 3). A)
Glucose levels of control, nondiabetic rats during a severe hypoglycemic clamp. With
insulin infusion and careful glucose infusion, plasma glucose levels are decreased over
a 2 ½ hour period to 15 mg/dl (time 0). Severe hypoglycemia is held for 1 ½ hours or
until death. B) Mortality associated with severe hypoglycemia started as early as 25
minutes into severe hypoglycemia with 50% mortality at 50 minutes into severe
hypoglycemia. All rats had died 90 minutes into severe hypoglycemia. C) Heart rate
during the clamp remains normal until just before severe hypoglycemia when glucose
levels reach ~35 mg/dl at which time heart rate increases. At the onset of severe
hypoglycemia, heart rate decreases. Heart increases again immediately prior to death.
The slower heart rates that occur towards the end of the clamp can be attributed to
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multiple cardiac arrhythmias associated with bradycardia. D) QTc prolongation starts to
occur during insulin infusion when glucose levels are moderately hypoglycemic (~35
mg/dl) and persists into severe hypoglycemia. Mean QTc during severe hypoglycemia
increased to 158+5 ms compared to 122+2 ms in the basal period (p<0.01). E)
Epinephrine levels increased from 495+60 in the basal period and peak at 3034+383
pg/ml at the onset of severe hypoglycemia, but decline as severe hypoglycemia persists
(p<0.001). F) Norepinephrine levels increased from 197+20 in the basal period and start
to increase at the onset of severe hypoglycemia and continue to rise throughout severe
hypoglycemia, peaking at 748+116 pg/ml (p<0.001). n=6; Data expressed as
mean+sem.

108

Figure 22. ECG changes in response to severe hypoglycemia (study 3).
Electrocardiogram (ECG) recordings from one representative control rat from basal
(euglycemia) through severe hypoglycemia induced death. The order of the graphs is a
typical representation of what occurs in all rats during severe hypoglycemia and just
prior to death. At the top of the left column, the ECG shows a rat in normal sinus rhythm
during euglycemic conditions. During moderate hypoglycemia, cardiac arrhythmias are
rarely witnessed. At the start of severe hypoglycemia, heart rate tends to return to basal
levels followed by QTc prolongation and the initiation of several types of cardiac
arrhythmias. Cardiac arrhythmias that occur during severe hypoglycemia are premature
atrial contractions (PAC noted by arrow), premature ventricular contractions (PVC noted
by arrow), nonsustained ventricular tachycardia (v-tach), 1st degree heart block (PR
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prolongation noted by arrow), and occasional 2nd degree heart block (absent QRS
complex noted by arrow). With severe hypoglycemia of increased duration, frequency
of 2nd degree heart block increases followed by 3rd degree heart block. At the time
cardiorespiratory arrest, heart rate is markedly decreased.
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Figure 23. Arrhythmias, blood gas, and blood pressure in response to severe
hypoglycemia in control experiments (study 3). A) Frequency of both PVCs and 2nd
degree heart block occur at a rate of 1.4+0.74 and 2+0.78 per minute, respectively,
during severe hypoglycemia. B) 3rd degree heart block occurred in 100% of the rats and
v-tach occurred in 75% of the rats. C) Oxygen (open diamond, left axis) and carbon
dioxide (black square, right axis) levels remain normal during severe hypoglycemia
(97% O2 and 32 mmHg CO2). During apnea and just prior to death, oxygen levels
decrease (38+6%) and carbon dioxide levels increase (53+3 mmHg). D) Blood pressure
increased at the start of severe hypoglycemia and remained elevated throughout severe
hypoglycemia. Blood pressure decreased as the rats died. n=6. Data expressed as
mean+sem.
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Figure 24. Electroencephalogram (EEG) recordings in response to hypoglycemia
in a control rat during a hyperinsulinemic/severe hypoglycemia clamp (study 3).
The progressive series of EEG recordings initially shows basal brain activity during the
euglycemic state followed by slow, high amplitude brain waves, characteristic of severe
hypoglycemia. Isoelectric activity on the EEG corresponded to rats in a comatose state.
The sudden onset of chaotic, high amplitude EEG voltages of short duration (~5
seconds) corresponded to visible tonic-clonic seizure-like behavior.
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Figure 25. Severe hypoglycemic clamp with ICV glucose infusion (study 4). A)
Mortality due to severe hypoglycemia was significantly reduced from 89% in ICV
mannitol to 33% in ICV glucose infused rats (*p<0.05 Fisher exact test, Freeman-Halton
extension). B) Blood glucose levels were evenly matched between the ICV mannitol
(white circle) and ICV glucose (black circle) infused rats. Once blood glucose levels
reached 15 mg/dl, severe hypoglycemia was started (time 0). Severe hypoglycemia was
held for a duration of 3 hours. C) Mean glucose infusion rates during severe
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hypoglycemia were significantly elevated in ICV glucose (black bar) infused rats
(5.4+0.6 mg/kg/min) compared to ICV mannitol (white bar) infused rats (4.2+0.41
mg/kg/min). *p<0.01 ttest. D) Heart rate remained normal compared to basal in both
groups until 45 minutes into severe hypoglycemia when ICV mannitol infused rats had
elevated heart rate. ICV glucose infused rats had lower heart rates throughout severe
hypoglycemia compared to ICV mannitol infused rats. Mean heart during severe
hypoglycemia was 414+9 BPM and 357+8 in ICV mannitol and ICV glucose infused
rats, respectively (*p < 0.05 ttest). E) The QTc length was increased after the start of
insulin infusion during moderate hypoglycemia and reached statistical significance at 30
minutes into insulin infusion. During severe hypoglycemia, QTc length was not different
between ICV mannitol and ICV glucose infused rats with mean QTc values of 180+2
and 187+3 ms, respectively. F) Norepinephrine levels were increased during severe
hypoglycemia in ICV mannitol infused rats compared to the basal state, but this
response was blunted in ICV glucose infused rats. *p<0.05, ttest. n=9/group. Data
expressed as mean+sem.
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Figure 26. Mortality and arrhythmia incidence in ICV glucose infusion (study 4). A)
Mortality incidence was associated with duration of sinus tachycardia (heart rates
greater than 400 bpm). Tachycardia lasting <15 minutes resulted in no mortality.
Tachycardia lasting 16-30 minutes resulted in 17% and 20% death in the ICV mannitol
and ICV glucose infused rats, respectively. Tachycardia lasting longer than 30 minutes
led to 80% death in ICV mannitol infused rats but only 50% death in ICV glucose
infused rats. B) The incidence of mortality increased with increased duration of
ventricular

depolarization/repolarization

dispersion

as

noted

by

greater

QTc

prolongation. Basal QTc duration was 122+2 ms but increased in response to
hypoglycemia. Increased QTc lengths of 150-179 ms did not increase mortality.
Increased QTc lengths of 180-200ms was associated with 14 and 13% mortality in ICV
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mannitol and ICV glucose infused rats, respectively. QTc lengths of more than 200 ms
was associated with 83% mortality in ICV mannitol infused rats but only 40% in ICV
glucose infused rats. C) During severe hypoglycemia, the frequency of premature
ventricular contractions (PVCs) was nonsignificantly reduced from 2.2+1.2 per minute in
ICV mannitol to 0.54+0.32 per minute in ICV glucose infused rats (p = 0.07). D) During
severe hypoglycemia, the frequency of 2nd degree heart block was 2.6+0.66 and
1.1+0.45 per minute for ICV mannitol and ICV glucose infused rats (p=NS). E) During
severe hypoglycemia, the incidence of 3rd degree heart block was 89% and 38% for the
ICV mannitol and ICV glucose infused rats (*p<0.05). F) Ventricular tachycardia (v-tach)
during severe hypoglycemia occurred in 38% of the ICV mannitol infused rats but none
of the ICV glucose infused rats experienced v-tach (p=NS). white circle/bar= ICV
mannitol; black circle/bar= ICV glucose. *p<0.05, ttest. n=9/group. Data expressed as
mean+sem.
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Figure 27. Severe hypoglycemic clamp with adrenergic blockade (study 5). A)
Control rats had a mortality rate of 33% (n=12) in response to severe hypoglycemia.
Alpha blockade had no effect on mortality (50%; n=6). Death was prevented in both 
(n=13) and  blocker (n=5) infused rats (*p<0.029, Fisher exact test, Freeman-Halton
extension). B) Glucose levels were evenly matched throughout the clamp. Glucose was
clamped between 10-15 mg/dl for 3 hours. C) Mean glucose infusion rate during severe
hypoglycemia.  blockade significantly increased glucose infusion rate. Alpha
blockade and beta blockade alone did not differ compared to controls but  blocker rats
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had lower glucose infusion rate compared to  blocker and  blocker infused rats
(p<0.05, ANOVA). D) Heart rate was consistently lower in  and  blockade rats
throughout the clamp compared to control and  blockade rats (*p<0.001 for individual
timepoints, ANOVA). E) QTc length was significantly increased in all groups during
severe hypoglycemia (p<0.001, ANOVA). Combined / blockade significantly blunted
the QTc prolongation compared to controls (*p<0.001 for mean QTc during severe
hypoglycemia, ANOVA). White circle= control; black circle= (a/b) blocker; white
triangle=  (a) blocker; black triangle=  (b) blocker. Data expressed as mean+sem.
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Figure 28. Insulin levels, mortality incidence and blood pressure levels during
severe hypoglycemia with or without adrenergic blockade (study 5). A) Insulin
levels were not different among the groups in the basal or severe hypoglycemia periods.
B) Incidence of severe hypoglycemia induced death was increased with duration of
sinus tachycardia (defined as >400BPM). Tachycardia did not develop in  or 
blocker rats. Alpha blockade rats all died with less than 15 minutes of tachycardia
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whereas control rats had 100% mortality with more than 30 minutes of tachycardia. C)
Incidence of mortality increased with QTc length. During severe hypoglycemia, rats that
had a QTc prolongation of 150-179ms all survived, whereas in rats where hypoglycemia
increased QTc lengths to 180-200ms there was an associated increase in mortality to
25% in control rats. In control and alpha blockade rats, QTc prolongation of more than
200ms resulted in 33% and 67% mortality, respectively. D and E) Systolic (D) and
diastolic (E) blood pressure (BP) during severe hypoglycemia were lower in  blocker
infused rats compared to controls (*p<0.001 Two-way ANOVA). White bar= control;
black bar= (a/b) blocker; diagonal slash=  (a) blocker; horizontal slash=  (b)
blocker. n=5-13. Data expressed as mean+sem.
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Figure 29. Severe hypoglycemia induced arrhythmias and catecholamines levels
during adrenergic blockade (study 5). A) As compared to control rats, PVC frequency
during severe hypoglycemia was significantly decreased in  and  blockade rats (*p
< 0.001, ANOVA) with a trend for decreased frequency in  blockade rats. B) Second
degree heart block frequency was significantly reduced in  blockade rats with only 1
rat experiencing 2nd degree heart block. Alpha and beta blockade alone trended to
reduce frequency of 2nd degree heart block but this was not significantly different
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compared to controls. C) Incidence of 3rd degree heart block was 40% in control rats
and 16% in  blockade rats. No 3rd degree heart block occurred in  or  blockade
rats. (*p<0.02 Fisher exact test, Freeman-Halton extension). D) Epinephrine levels
increased significantly in all groups during severe hypoglycemia. The beta blockade
group had significantly higher epinephrine levels compared to all other groups. (*p<0.01
ANOVA) E) Norepinephrine levels increased significantly in all groups during severe
hypoglycemia. Norepinephrine levels in the alpha blockade group were significantly
higher compared to all 3 other groups. (*p<0.001 ANOVA). White bar= control; black
bar= (a/b) blocker; diagonal slash=  (a) blocker; horizontal slash=  (b) blocker.
n=5-13. Data expressed as mean+sem.
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Severe
Basal

Hypoglycemia

Pre-death

Epinephrine

495

2561a

n/a

(pg/ml)

+60

+345

Norepinephrine

197

743a

(pg/ml)

+20

+103

Oxygen (SO2%)

98

97

38a

+0.2

+1.5

+5.7

Carbon Dioxide

31

31

53a

(mmHg)

+1.3

+0.79

+2.8

Potassium

4.16

2.96a

4.46

(mmol/l)

+0.15

+0.06

+0.36

pH

7.45

7.44

7.22a

+0.01

+0.01

+0.03

0.89

0.96

0.9

+0.07

+0.08

+0.09

Bicarbonate

21.7

21.9

20.5

(mmol/l)

+0.97

+0.49

+0.78

Calcium (mmol/l)

n/a

Table 1. Hormones and arterial blood gas and electrolytes in control experiments
(study 3). Epinephrine and norepinephrine increased during severe hypoglycemia.
Oxygen and carbon dioxide levels remain normal during severe hypoglycemia
compared to basal. Just prior to death, oxygen levels decrease and carbon dioxide
levels increase. Potassium levels slowly decline during insulin infusion with significantly
lower potassium levels during severe hypoglycemia. Just before death, potassium
levels increase. pH levels remain normal throughout severe hypoglycemia but just prior
to death. Calcium and bicarbonate levels were not significantly different throughout the
clamp. ap<0.05 vs basal. n=6. Data represented as mean+sem.
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Severe
Basal
MAN

Hypoglycemia
GLU

MAN
a

GLU

Pre-death
MAN

GLU

N/A

N/A

N/A

N/A

a

Glucose

86

86

12

12

(mg/dl)

+3

+4

+0.09

+0.16

Insulin

166

128

7482a

8828a

(pg/ml)

+14

+51

+776

+492

Epinephrine

79

67

1926a

2155a

1453a

1677a

(pg/ml)

+30

+12

+320

+448

+872

+1306

Norepinephrine

181

181

1441a

464ab

2371a

3010a

(pg/ml)

+27

+17

+646

+48

a

+1785

+1697

ab

3.14

4.25

3.95

Potassium

4.66

4.43

3.58

(mmol/l)

+0.13

+0.13

+0.14

+0.17

+0.3

+0.24

Oxygen

97

97

96

98

35a

18a

(SO2%)

+0.23

+0.29

+1.8

+0.13

+10

+0.18

Carbon Dioxide

29

31

27

31

47a

53a

(mmHg)

+0.49

+0.65

+1.3

+1.24

+3.3

+5.1

Respiration

94

95

85

78a

30a

54a

(breaths/min)

+3

+4

+4

+4

+9

+28

Table 2. Glucose, hormones, and arterial blood gas and electrolytes for ICV
glucose study (study 4). Blood glucose levels were evenly matched during severe
hypoglycemia in both ICV mannitol (MAN) and ICV glucose (GLU) groups. Insulin
increased to a similar extent in the severe hypoglycemic clamp in both groups.
Epinephrine and norepinephrine increased during severe hypoglycemia to the same
extent in both groups. Just prior to death, norepinephrine increased in both treatment
groups. Potassium decreased to a similar extent in both groups during severe
hypoglycemia. Blood oxygen and carbon dioxide remained normal during severe
hypoglycemia compared to the basal state. Blood oxygen levels decreased, and carbon
dioxide levels increased, in rats that died in both groups immediatel prior to death,.
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Respiration remained normal in control rats during severe hypoglycemia but ICV
glucose infused rats had lower respiration compared to the basal state. Prior to death,
respiration significantly decreased in both groups. ap<0.05 vs basal, bp<0.05 vs control,
ttest. n=9/group. Data represented as mean+sem.
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CON

 blockers

 blocker

 blocker

Glucagon

3733

4137

10096b

4559

(AUC)

+1342

+751

+1192

+483

4.4

4.0

4.7

5.0

+0.14

+0.11

+0.09

+0.14

Severe

3.12a

2.84a

3.01a

3.74ab

Hypoglycemia

+0.18

+0.08

+0.21

+0.05

3.6

N/A

4.2

N/A

Basal
Potassium
(mmol/l)

Pre-Death
Basal
Oxygen
(SO2%)

+0.48

+0.21

96

97

97

97

+1.9

+0.28

+0.3

+0.32

Severe

97

98

98

98

Hypoglycemia

+0.34

+0.15

+0.36

+0.14

a

Pre-Death
Basal
Carbon Dioxide
(mmHg)

26

N/A

+12

a

35

N/A

+0.28

32

33

32

34

+1.7

+0.69

+0.87

+0.91

36

42ab

ab

Severe

32

Hypoglycemia

+1.4

+0.97

+2.2

+2.2

48a

N/A

63a

N/A

Pre-Death
Basal

+2.5

+11

86

88

96

86

+4

+4

+8

+4

Respiration

Severe

76

(breaths/min)

Hypoglycemia

+3
28a

Pre-Death

38

ab

66

54ab

+2

+8

+2

N/A

8

N/A

51

a

+8

Table 3. Glucagon, arterial blood gas and electrolytes for adrenergic blockade
study (study 5). Glucagon area under the curve (AUC) was greater in alpha blockade
rats and similar between combined alpha/beta and beta blockade rats compared to
controls. Potassium levels decreased in all groups during severe hypoglycemia. Beta
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blockade resulted in higher potassium levels during severe hypoglycemia compared to
controls. Oxygen saturation remained normal in all groups throughout severe
hypoglycemia. Prior to death in control and alpha blocker infused rats, oxygen
decreased compared to basal. Carbon dioxide was higher during severe hypoglycemia
in , , and  blocker infused rats compared to basal and control. Just prior to death
in control and blockade rats, carbon dioxide levels increased. Respiration was
significantly decreased during severe hypoglycemia in , , and  blocker infused rats
compared to basal. Respiration was lower during severe hypoglycemia in  and 
blocker infused rats compared to controls. Respiration decreased just prior to death in
control  blocker infused rats. ap<0.05 vs basal, bp<0.05 vs control. n=5-13; Data
represented as mean+sem.
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Discussion
Mortality due to iatrogenic insulin administration represents a major concern for
insulin treated diabetic patients and their families. Determining the mechanisms by
which hypoglycemia induces sudden death is critically important in order to find
treatments to protect patients who are at risk. Animal studies are needed to investigate
the causes of mortality associated with severe hypoglycemia. In the current study,
diabetes was found to exacerbate, while recurrent hypoglycemia was found to
attenuate, severe hypoglycemia-induced sudden death. The cause of death in these
preliminary rat studies was unknown. Cardiac arrhythmias have been shown to occur
during moderate hypoglycemia in humans88 and fatal cardiac arrhythmias are
speculated to mediate the “dead in bed syndrome” but no studies to date have shown
this as it is difficult to investigate in the clinical setting. Using a rat model, we show for
the first time that fatal cardiac arrhythmias occur as a result of severe hypoglycemia and
such arrhythmias can be reduced by ICV glucose infusion and prevented by beta
adrenergic blockade. These results indicate that brain neuroglycopenia and the
sympathoadrenal response mediate fatal cardiac arrhythmias that occur during severe
hypoglycemia (figure 30).
Diabetes increased mortality due to severe hypoglycemia although the
mechanism(s) involved remains unclear. Uncontrolled diabetes is hypothesized to
increase risk of fatal cardiac arrhythmias. Diabetes has been shown in animal models to
alter the myocardium composition152 and lead to cardiac mechanical defects such as
defects in left ventricular function and velocity ejection 153. Aside from chronic
maladaptations associated with insulin deficiency, it may be that the greater absolute
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decrement in blood glucose in diabetic (eg, from 348 to 12 mg/dl) versus control rats
(from 88 to 12 mg/dl) may have contributed to overall increased mortality by inducing a
greater net insult going from high to low glucose levels. Although STZ diabetic rats have
been shown to be at higher risk for arrhythmias154, in the absence of ECG data from
these preliminary experiments, the cause of increased mortality rates in diabetic rats
remains unknown.
Recurrent hypoglycemia significantly reduced severe hypoglycemia-induced
mortality. These findings are consistent with a pre-conditioning effect of recurrent
hypoglycemia to limit severe hypoglycemia induced seizures, brain damage and
cognitive dysfunction60. It is speculated that the blunted catecholamine response that
occurred with recurrent hypoglycemia may be the mechanism by which recurrently
hypoglycemic rats were protected from death. Interestingly, the blunted catecholamine
response in the recurrently hypoglycemic rats apparently rendered them more prone to,
but paradoxically less vulnerable to, an otherwise lethal episode of severe
hypoglycemia. This putative mechanism is supported by the beta blockade treatment
study that noted reduction of arrhythmias and prevention of death. In the absence of
ECG recordings though, the extent to which cardiac arrhythmias were reduced by
antecedent recurrent hypoglycemia is unknown.
As compared to human ECG recordings, rat ECGs are characterized by shorter
interval durations, more rapid heart rate, absent Q waves, and absence of an isoelectric
ST segment155. Supporting our assertion that the reported ECG changes truly reflect
ECG responses in humans, similar to the presented rate and rhythm disturbances noted
by ECG monitoring in the current rat study, clinical ECG observations during
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hypoglycemia include QTc prolongation87-89,156, sinus bradycardia85,156, and multifocal
ventricular ectopies85. Furthermore, rats respond to the effects of anti-arrhythmic agents
such as adrenoreceptor blockers similar to humans as seen previously in a rat model in
which combined alpha and beta adrenergic receptor blockade reduced sinus
tachycardia and ST elevation induced by immobilization stress98. Taken together, the rat
ECG changes presented in these studies closely resemble those observed in humans
during hypoglycemia, indicating that beta blockers have clinical significance to prevent
severe hypoglycemia-induced cardiac arrhythmias and sudden death.
The mechanisms regulating severe hypoglycemia-induced sudden death are
thought to be multifactorial; however, in these experiments a timeline of events leading
to sudden death (Figure 31) can be summarized as follows: 1) In the setting of
hyperinsulinemia, mild hypokalemia and mild QTc prolongation manifest first, even
during euglycemic conditions. 2) As glucose levels are further lowered, potassium levels
continue to drop even further and QTc prolongation increases reaching its maximum
during severe hypoglycemia. Rarely, minor cardiac arrhythmias, such as PACs, are
witnessed during more moderate levels of hypoglycemia (20-40 mg/dl) but were never
witnessed during euglycemic conditions. 3) At the onset of severe hypoglycemia,
epinephrine levels peak. 4) Cardiac arrhythmias develop shortly after, including PVCs,
1st and 2nd degree heart block, ventricular tachycardia, and atrial fibrillation. 5)
Norepinephrine levels peak near 1 hour of severe hypoglycemia. 6) Shortly thereafter,
sinus tachycardia occurs, and if not spontaneously corrected is very predictive of
ensuing death. 7) In rats that die, sinus tachycardia is followed by increased frequency
of PVCs and high grade 2nd degree heart block. 8) If sinus tachycardia is not
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spontaneously reversed, 3rd degree heart block is most often seen as the terminal
cardiac rhythm that is associated with profound bradycardia followed by the rapid
sequential onset of reduced cardiac output (noted by hypotension), respiratory
depression, hypoxemia, hypercarbia, and acidosis. Sinus tachycardia and 3 rd degree
heart block were the strongest predictors of sudden death due to hypoglycemia. The
sensitivity and specificity of sinus tachycardia (hear rate > 400 bpm) as a predictor of
mortality was 88% and 74%, respectively, while 3rd degree heart block was 89% and
95%, respectively. Other predictors of mortality in the current experiments were QTc
prolongation and increased frequency of 2nd degree heart block. The sensitivity and
specificity of QTc prolongation (>200ms) as a predictor of mortality was 81% and 60%,
respectively, while the sensitivity and specificity of 2 nd degree heart block was 94% and
53%, respectively.
Moderate hypoglycemia has been previously shown to lead to QTc prolongation,
which is known to be proarrhythmic85-89. In the present studies, severe hypoglycemia
induced a significant increase in QTc length indicating that hypoglycemia induces a type
of acquired long-QTc syndrome. QTc lengthening was associated with increased risk of
mortality. With adrenergic blockade, blunting the rise in QTc during hypoglycemia may
have contributed to the reduced incidence of arrhythmias and ultimately the prevention
of death. However, hypoglycemia induced QTc prolongation in beta blocker and ICV
glucose infused rats were similar to their respective controls indicating that QTc
prolongation per se does not lead to cardiac arrhythmias and death. Since providing the
brain with glucose reduced mortality but did not reduce QTc prolongation, it is
concluded that systemic factors such as low glucose, low potassium, and elevated
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epinephrine levels that affect ventricular dispersion, and not neuroglycoenia per se, that
regulate QT length. Taken together, these studies indicate that QTc prolongation is a
marker of severe hypoglycemia and is predictive of ensuing cardiac arrhythmias, but is
not sufficient to cause cardiac arrhythmias.
A role for potassium in regulation of cardiac arrhythmias has been noted88,97.
Hypokalemia can trigger cardiac arrhythmias during moderate hypoglycemia in
humans88. In addition, potassium supplementation in the current studies trended to
reduce mortality in non-diabetic and diabetic rats indicating that hypokalemia increases
risk of death due to severe hypoglycemia. However, because the mortality differences
were not significant, it is still undetermined to what extent hypokalemia regulates severe
hypoglycemia induced sudden death.
Blood potassium levels are known to be regulated by insulin, adrenergic
activation and pH, each of which affects potassium entry into cells157. 1) Insulin is
known to lower plasma potassium levels by increasing potassium entry into cells. Insulin
was shown to lower blood potassium levels during euglycemic conditions during the
clamps but hypokalemia did not cause cardiac arrhythmias in this euglycemic setting
indicating that low glucose levels are required in addition to hypokalemia to cause
arrhythmias. 2) Beta and alpha adrenergic receptor stimulation are known to increase
and decrease potassium entry into the cell thus resulting in decreased and increased
potassium in the blood, respectively. In the current studies, beta blockade led to
significantly higher blood potassium levels whereas alpha blockade led to a
nonsignificant decrease in potassium levels during the clamp. Interestingly, combined
alpha/beta blockade led to similar blood potassium levels as controls. This indicates that
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although potassium levels were higher in the beta blockade group, this is not
necessarily why mortality was prevented in this group because combined alpha/beta
blockade resulted in potassium levels similar to controls yet all rats in this group lived. 3)
Finally, acidosis is known to impair potassium entry into the cell thus leading to elevated
plasma potassium. pH levels did not change during the clamps until just before death
when acidosis occurred. When acidosis occurred it was also noted that hyperkalemia
was present. However, hyperkalemia is not considered a cause of death but rather a
result of acidosis. Taken together, the results from these studies indicate that the level
of hypokalemia achieved in the setting of insulin induced hypoglycemia was not
sufficient, or not of sufficient magnitude, to cause lethal cardiac arrhythmias.
Cardiac arrhythmias can also result from changes in respiration. In the current
studies, the respiratory rate decreased slightly as the rats entered a severe
hypoglycemia-induced coma, but the respiratory rate declined to a similar extent in all
groups, although sometimes lower with beta blockade. Since there was no difference in
the respiratory rate and since oxygen and carbon dioxide levels did not change during
the clamps, it can be concluded that respiratory arrest developed only after cardiac
arrest. Therefore, defects in respiration or respiratory drive, including brief post-ictal
apneic episodes, are not primary contributors to severe hypoglycemia-induced sudden
death but rather occur following a terminal cardiac arrhythmia.
Another potential contributor to cardiac arrhythmias is marked changes in blood
pressure. During severe hypoglycemia, decreased cardiac output and resultant
hypotension could lead to decreased blood flow to the brain and/or heart thereby
increasing risk for fatal cardiac arrhythmias. However, based on the current studies,
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blood pressure was maintained throughout the period of severe hypoglycemia and was
therefore not thought to contribute to severe hypoglycemia induced mortality. In the
control experiments from study 3, blood pressure was elevated during severe
hypoglycemia and only dropped following a terminal bradycardic arrhythmia. It is
surmised that hypotension did not contribute to cardiac death, but rather was a marker
of sudden cardiac failure.
In addition to the above mentioned peripheral effects of insulin-induced severe
hypoglycemia, central effects on hypoglycemic counterregulation are also important. In
particular, the hypothalamus plays a critical role in regulating the hypoglycemic
counterregulatory response. Low glucose in the ventromedial hypothalamus (VMH) is
required for local release of norepinephrine15 which leads to increased adrenergic
signaling and epinephrine release from the adrenal gland. Since glucose infusion into
the VMH blunts the counterregulatory response to hypoglycemia in a dose dependent
manner158 and brain centers are known to control heart contractility and respiration 159, it
was hypothesized that if the brain has an adequate glucose supply during a
hyperinsulinemic/severe hypoglycemic clamp, then cardiac arrhythmias and mortality
would be reduced. Consistent with previous studies using a low dose of ICV glucose
infusion158, the ICV glucose dose infused in the current study was not enough to blunt
the epinephrine response; however, the norepinephrine response was blunted.
Interestingly, the blunted norepinephrine response during ICV glucose infusion may
have contributed to reduced mortality. Although epinephrine remained elevated, heart
rate in the ICV glucose infused rats was normal possibly due to the blunted
norepinephrine response and/or an increased vagal tone. Reduced mortality rate with
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ICV glucose infusion reveals that the brain plays an important role in maintaining normal
heart rate and reducing cardiac arrhythmias during severe hypoglycemia even in the
presence of elevated epinephrine. It can be concluded from the current studies that
brain neuroglycopenia contributes to severe hypoglycemia-induced cardiac arrhythmias
and mortality. Further research should focus on how cellular changes in brain glucose
sensing and efferent pathways that occur during severe hypoglycemia may contribute to
sudden death.
Hypoglycemic seizures were also noted to occur in most rats. However, with the
exception of the recurrent hypoglycemia protocol, even though the incidence of seizures
tended to be reduced in some studies, there was no correlation found between number
of visible seizure-like activity and survival benefit. Consistent with other studies
demonstrating survival following hypoglycemia induced seizures60,61 these current
studies indicate that seizures are not a primary contributor to severe hypoglycemiainduced mortality but rather serve as a marker of severe hypoglycemia.
Whether central or systemic, the rise in catecholamines during severe
hypoglycemia was hypothesized to increase risk of cardiac arrhythmias and sudden
death. By blocking the effects of catecholamines (epinephrine and norepinephrine) with
simultaneous / or single  adrenergic receptor blockers during a hyperinsulinemic,
severe hypoglycemic clamp, glucose infusion rate increased, heart rate decreased, and
cardiac arrhythmias were reduced. The major finding of these studies is that combined
alpha/beta and single beta adrenergic blockade prevented death. These studies
indicate that enhanced catecholamine signaling through beta adrenergic receptors
mediates fatal cardiac arrhythmias in the setting of severe hypoglycemia.
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Beta blockade (propranolol) is known to reduce the clearance of epinephrine and
norepinephrine. This correlates with the observed increased epinephrine in the beta
blockade group and the trend for an increased norepinephrine160. Similarly, alpha
blockade (phentolamine) has been shown previously to double plasma norepinephrine
levels160, which in the present study norepinephrine was increased 2.8 fold with
prazosin.
Although adrenergic receptors located within the brain have been shown to be
involved in mediating the counterregulatory response 36, the current study cannot
distinguish whether the adrenergic blocker effect was mediated via central or peripheral
actions. However, regardless of their site of action, their effect was profound. It is
speculated that the beta-adrenergic norepinephrine response, may be the lethal
arrhythmogenic provocateur, based on the following observations: 1) epinephrine levels
peaked early, at the onset of severe hypoglycemia, then declined before the onset of
serious arrhythmias; whereas norepinephrine levels continued to rise during severe
hypoglycemia and peaked immediately before the time of arrhythmogenic death, 2) the
reduced rates of hypoglycemia-induced arrhythmias and deaths with ICV glucose
infusion was associated with a blunted norepinephrine response and not a blunted
epinephrine response, and 3) beta, not alpha adrenergic blockade, markedly reduced
arrhythmias and completely prevented death, even in the presence of high epinephrine
levels. Taken together, it is proposed that it was the hypoglycemia-induced increased
norepinephrine response, acting primarily via beta adrenergic receptors, that mediated
the severe hypoglycemia-induced fatal cardiac arrhythmias.
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Cardiac specific beta blockers (ie, β1 blockers), that do not adversely limit the
counterregulatory response to hypoglycemia, have been shown to prevent QTc
prolongation associated with moderate hypoglycemia88. In the current study, nonselective beta-blockade did not prevent QTc prolongation, but more importantly,
reduced the incidence of life-threatening arrhythmias and overall mortality associated
with severe hypoglycemia. Future research is needed to investigate potential life-saving
effects of adrenergic 1 and/or 2 receptor blockade in the setting of hypoglycemia.

Summary
Under the conditions studied, diabetes worsens, while recurrent antecedent
hypoglycemia protects against severe hypoglycemia-induced mortality. Thus, the odds
of surviving an episode of severe hypoglycemia are dependent on antecedent blood
sugar control. Seizures are markers of severe hypoglycemia, but are not sufficient to
cause death. Under the conditions studied, severe hypoglycemia-induced sudden death
is caused by fatal cardiac arrhythmias. Deaths due to severe hypoglycemia were
mediated by brain neuroglycopenia and the counterregulatory sympathoadrenal
(adrenergic) response that lead to fatal cardiac arrhythmias (3 rd degree heart block with
a slow ventricular response) causing low cardiac output (hypotension) followed by
respiratory arrest. Implications of the current studies could lead to improvement in
treatment strategies that aim to reduce mortality of individuals at high risk for insulininduced hypoglycemia.
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Figure 30. Proposed mechanism of sudden cardiac death due to insulin-induced
severe hypoglycemia. Hypoglycemia is detected at the level of the brain. Through
autonomic innervation, local release of norepinephrine at nerve terminals within the
heart may lead to fatal cardiac arrhythmias. Autonomic innervation of the adrenal gland
results in epinephrine release. Both circulating epinephrine in addition to circulating
norepinephrine act at the level of the heart to increase risk of fatal cardiac arrhythmias.
Within the blood, hypokalemia is also thought to contribute to hypoglycemia induced
cardiac arrhythmias. Both these direct and indirect actions on the heart lead to QTc
prolongation, but QTc prolongation is not thought to be a major contributor to mortality.
Hypoglycemia induced sudden cardiac death results from enhanced adrenergic
signaling at the level of the heart that leads to sinus tachycardia. Tachycardia is
followed by 3rd degree heart block that culminates into a fatal bradycardic rhythm
causing cardiorespiratory failure and sudden death. Red= circulating glucose,
electrolytes, and hormones; blue= autonomic innervation
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Figure 31. Timeline of events leading to severe hypoglycemic sudden death.
During hyperinsulinemic/euglycemic conditions when glucose is ~79 mg/dl, hypokalemia
occurs and QTc prolongation begins. During moderate levels of hypoglycemia (~40
mg/dl), PACs occur occasionally. At the start of severe hypoglycemia (15 mg/dl),
epinephrine peaks. As severe hypoglycemia prolongs, hypokalemia worsens, QTc
prolongation peaks, and cardiac arrhythmias develop (PVCs and 1 st and 2nd degree
heart block). Norepinephrine peaks around 1 hour into severe hypoglycemia and is
followed by tachycardia. If tachycardia is followed by a return to normal sinus rhythm,
the rat survives. If tachycardia is followed by an increase in the frequency of PVCs and
2nd degree heart block, then 3rd degree heart block associated with bradycardia will
manifest and lead to sudden cardiac death. PAC= premature atrial contraction, PVC=
premature ventricular contraction
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Chapter 5: Thesis Discussion
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Regulation of glucose homeostasis involves coordination between liver, muscle,
adipose tissue, and brain. The major understanding of the pathogenesis of insulin
resistance characterized by Type 2 diabetes stems from research on skeletal muscle
and adipose tissue in which a reduced ability to translocate GLUT4 to the plasma
membrane in these tissues characterizes glucose intolerance and insulin resistance1,2.
In recent years, the role of the brain in regulating overall energy homeostasis has been
emphasized. In particular, the hypothalamus consists of integrated neural networks with
both efferent and afferent pathways leading to and from the periphery, respectively, to
control whole body glucose homeostasis. Therefore, studying the role of brain glucose
sensing in the settings of both euglycemic and hypoglycemic conditions is important to
understanding the etiology of normal glucose homeostasis and altered glucose
homeostasis as occurs in conditions such as insulin resistance in diabetes.

Glucose transporter 4
GLUT4 is an insulin responsive glucose transporter that is required in muscle
and/or adipose for normal glucose homeostasis. To emphasize the important role for
GLUT4 in mediating glucose homeostasis, GLUT4 knockout in skeletal muscle and
adipose tissue leads to glucose intolerance and insulin resistance, hallmarks of Type 2
diabetes1,2. GLUT4 is also present in the brain with differential regional expression in
hypothalamus, hippocampus, cortex, cerebellum, and other regions 21. Since the
hypothalamus is an important neural center that mediates many metabolic regulatory
pathways, understanding GLUT4 action in this region is integral to understanding
normal glucose homeostasis.
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Insulin action in the brain is known to control hepatic glucose production and the
counterregulatory response to hypoglycemia27,106,124. Many glucose sensing neurons
located within the hypothalamus contain both insulin receptor and GLUT416. In addition,
neuronal insulin receptor knockout (NIRKO) mice which exhibit impaired suppression of
hepatic glucose production and impaired hypoglycemic regulation also have reduced
hypothalamic GLUT4 protein expression27,106 indicating that decreased brain GLUT4
may be contributing to the observed phenotype of NIRKO mice. However, brain
GLUT4’s role in glucose homeostasis has not been clearly defined. As an insulin
sensitive glucose transporter, a role in glucose uptake in the brain would need to be one
of metabolic importance to be initiated only when insulin is present. Studies presented
in this thesis have revealed the importance of brain GLUT4 in mediating whole body
glucose homeostasis. Brain GLUT4 knockout mice exhibit glucose intolerance, hepatic
insulin

resistance,

regional specific

reduced

brain

glucose uptake,

impaired

hypoglycemic counterregulation, and impaired glucose sensing in VMH glucose
inhibited neurons. These novel findings will help guide therapeutic strategies aimed at
treating and preventing glucose intolerance and insulin resistance. Future research will
need to focus on understanding how differential regional expression of the various
glucose transporters regulate glucose metabolism and the counterregulatory response
to hypoglycemia.

Hypoglycemia
One of the major limitations in the treatment of diabetes is hypoglycemia. Well
controlled diabetes is essential for patients to prevent micro- and macrovascular
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complications associated with hyperglycemia; but avoidance of hypoglycemia can be
difficult. Severe hypoglycemia is clinically defined as a low blood sugar level during
which time the patient is unable, by themselves, to correct their low blood sugar (ie,
consume carbohydrates) and therefore require external assistance (from a family
member/friend or emergency services) in order to return glucose levels to normal. In the
lab, we define severe hypoglycemia as a glucose level of 10-15 mg/dl in order to
maintain consistency in all studies. Clinical case reports have indicated that severe
hypoglycemia can lead to brain damage, seizures, coma, and death, all of which are
observed in our rat model of insulin-induced severe hypoglycemia.
Brain damage due to hypoglycemia is disconcerting. Understanding how brain
damage is caused is essential in order to prevent hypoglycemia mediated brain damage
from occurring in diabetic patients at risk. In this thesis it was demonstrated that brain
damage can be affected by antecedent glucose control. Uncontrolled diabetes
exacerbates while insulin treated diabetes, that nearly normalizes blood glucose levels,
reduces severe hypoglycemia induced brain damage. Interestingly, no effects on
cognitive function were observed in this study. This indicates that although the duration
of hypoglycemia was enough to cause some brain damage, the extent of brain damage
was not of sufficient magnitude to translate into demonstrable cognitive deficits.
In addition to the brain damaging effects of severe hypoglycemia, perhaps an
even scarier reality is that severe hypoglycemia can be lethal. The ‘dead in bed’
syndrome refers to instances where otherwise healthy young individuals with Type 1
diabetes are found dead in their beds in the morning with no clear cause of death upon
autopsy69. Severe hypoglycemia has often been hypothesized to be the cause of death
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in this syndrome. A recent case report where a patient was found dead in their bed and
had been wearing a continuous glucose monitor revealed that severe hypoglycemia
occurred overnight just prior to death80. This was the first case report demonstrating
severe hypoglycemia associated with the dead in bed syndrome. However, how exactly
severe hypoglycemia leads to sudden death in humans is unknown. Ethical limitations
restrict the study of severe hypoglycemia in the human population. It has been
hypothesized that fatal cardiac arrhythmias result from severe hypoglycemia but to this
end has never been shown in clinical practice.
In this current thesis, it is shown for the first time in a rat model that severe
hypoglycemia leads to cardiac arrhythmias which lead to respiratory arrest. These fatal
cardiac arrhythmias can be reduced by providing the brain with glucose thus indicating
that neuroglycopenia plays an important role in mediating cardiac arrhythmogenic
deaths. Similarly, fatal cardiac arrhythmias were prevented by blocking beta
adrenorecptors indicating that the marked rise in epinephrine and norepinephrine likely
mediate cardiac arrhythmogenic deaths. These findings have direct clinical implications
in that, paradoxically, blocking the actions of the catecholamines during severe
hypoglycemia actually prevents death. These findings are consistent with the recurrent
antecedent

hypoglycemia

observations.

Rats

exposed

to

recurrent

moderate

hypoglycemia for 3 days followed by a hyperinsulinemic/severe hypoglycemic (10-15
mg/dl) clamp for 1 hour the following day had blunted sympathoadrenal responses
which was also associated with reduced mortality due to severe hypoglycemia. Thus,
consistent with the adrenoreceptor blockade study, blunted epinephrine response of
rats exposed to recurrent hypoglycemia was found to significantly improve overall
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survival. Interestingly, in human studies, beta blockade prevented the QTc prolongation
that normally occurs during moderate hypoglycemia88. Similarly in this thesis, betaadrenergic receptor blockade during severe hypoglycemia prevented both cardiac
arrhythmias and death. Beta blockers are already in use in heart failure patients and
improve their survival rates161. Taken together, fatal cardiac arrhythmias that occur in
the setting of severe hypoglycemia can be prevented with beta adrenergic blockade,
and future research should consider the use of beta blockade as a potential treatment in
diabetic patients at risk for severe hypoglycemic cardiac arrest.
In addition to the catecholamine surge, hypokalemia is known to be
proarrhythmic. Therefore, one of the goals to prevent severe hypoglycemia-induced
mortality

in

our

rat

model

was

to

supplement

potassium

during

the

hyperinsulinemic/severe hypoglycemic clamp. Severe hypoglycemia-induced mortality
trended to be reduced in both non-diabetic and diabetic rats that received potassium
supplementation but neither reached significance. Hypokalemia results from the
activation of sodium/potassium ATPases by insulin and, in the subsequent ECG
studies, hypokalemia occurred even prior to severe hypoglycemia. However,
hypokalemia is present at equal levels in several of the studies reported in this thesis,
including the beta blocker studies, indicating that hypokalemia itself is not sufficient to
cause sudden death during severe hypoglycemia. However, it remains undetermined
whether or not potassium infusion during episodes of hypoglycemia will prevent cardiac
arrhythmias.
A major question remains that if we can prevent sudden death due to severe
hypoglycemia, what will be the consequences of surviving such a severe episode?

145

Brain damage and cognitive defects as a result of severe hypoglycemia can
tremendously decrease quality of life. Therefore, future studies need to be aimed at
reducing severe hypoglycemia-induced brain damage and mortality simultaneously in
order to increase quality of life in patients at risk for the damaging effects of severe
hypoglycemia.

Summary
Understanding the pathogenesis of diabetes is crucial in order to reduce the rise
in diabetes prevalence. The complications of diabetes and diabetes treatments are also
important to study due to the very high incidence of diabetes in the world. The
mechanisms of the etiology of glucose intolerance and insulin resistance are well
defined in the periphery. However, the brain has an important role in glucose
homeostasis and has recently gained much attention. In addition, complications of
diabetes treatment remain a major concern for diabetic patients and their families. This
thesis reveals how brain centers control glucose tolerance and insulin sensitivity, and
how brain damage and mortality due to severe hypoglycemia can be prevented. First, it
was shown that brain GLUT4 is important in regulating hepatic glucose production and
the counterregulatory response to hypoglycemia in that knockout of brain GLUT4 led to
glucose intolerance, hepatic insulin resistance, and impaired hypoglycemic glucose
sensing. Second, antecedent blood glucose control regulates the extent of brain
damage induced by severe hypoglycemia in that insulin treatment that nearly
normalized blood glucose levels in diabetic rats reduced severe hypoglycemia-induced
brain damage compared to uncontrolled diabetic rats. Third, severe hypoglycemia
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induced mortality is mediated by fatal cardiac arrhythmias that can be reduced by brain
glucose infusion and prevented by beta adrenergic blockade indicating that brain
neuroglycopenia and enhanced catecholamine signaling are major contributing factors
to severe hypoglycemia-induced mortality.
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